var title_f16_59_17328="Bowel associated dermatosis";
var content_f16_59_17328=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Disseminated papulopustular hemorrhagic dermatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 297px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scattered papulopustular lesions due to neutrophilic infiltration of the skin is seen in the bowel- associated dermatosis arthritis syndrome in patients with inflammatory bowel disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Samuel Moschella, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_59_17328=[""].join("\n");
var outline_f16_59_17328=null;
var title_f16_59_17329="Yergasons test for biceps tendon";
var content_f16_59_17329=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1124px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/82897/Yergasons_test_biceps_video.mp4?title=Yergasons+test+for+biceps+tendon\" style=\"width:480px;height:288px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Yergasons test for biceps tendon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Yergasons test is used to assess the biceps tendon. It&nbsp;is performed with the patient's arm pronated and flexed at the elbow to 90 degrees. The patient then attempts to supinate the arm against a resisted isometric force applied by the examiner. Pain localized to the long biceps tendon marks a positive test.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Simons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_59_17329=[""].join("\n");
var outline_f16_59_17329=null;
var title_f16_59_17330="Achondroplasia 2";
var content_f16_59_17330=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Achondroplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 502px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This infant with achondroplasia has tibial bowing, frontal bossing, rhizomelia (the proximal limb segment, is shorter than the distal segment), and brachydactyly (short fingers).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Paul S Matz, MD. Reproduced from: Chung EK, Boom JA, Datto GA, Matz PS (Eds). Visual Diagnosis in Pediatrics. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_59_17330=[""].join("\n");
var outline_f16_59_17330=null;
var title_f16_59_17331="Perforated duodenal ulcer on computed tomography";
var content_f16_59_17331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perforated duodenal ulcer on computed tomography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 296px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Coronal reformatted computed tomography (CT) of the abdomen demonstrates extravasation of oral contrast through a hole in the duodenum (white arrow) consistent with a perforated duodenal ulcer. Note the&nbsp;inflammatory thickening of the duodenal wall (red arrow head).",
"    <br>",
"     (B) Axial CT scan of the abdomen demonstrates extravasation of oral contrast (white arrow) and inflammatory thickening of the duodenal wall (red arrow head) due to a perforated duodenal ulcer.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of J Pierre Sasson, MD.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_59_17331=[""].join("\n");
var outline_f16_59_17331=null;
var title_f16_59_17332="Acute ISN Light II";
var content_f16_59_17332=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light micrograph of kidney biopsy of a patient with acute interstitial nephritis showing eosinophils",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph with hematoxylin and eosin stain of acute interstitial nephritis showing diffuse interstitial infiltrate with many red-staining eosinophils. An uninvolved glomerulus is on the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_59_17332=[""].join("\n");
var outline_f16_59_17332=null;
var title_f16_59_17333="Clobetasol: Pediatric drug information";
var content_f16_59_17333=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clobetasol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"    see \"Clobetasol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/34/13860?source=see_link\">",
"    see \"Clobetasol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F152831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Clobex&reg;;",
"     </li>",
"     <li>",
"      Cormax&reg;;",
"     </li>",
"     <li>",
"      Olux-E&trade;;",
"     </li>",
"     <li>",
"      Olux&reg;;",
"     </li>",
"     <li>",
"      Temovate E&reg;;",
"     </li>",
"     <li>",
"      Temovate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F152832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Clobex&reg;;",
"     </li>",
"     <li>",
"      Dermovate&reg;;",
"     </li>",
"     <li>",
"      Mylan-Clobetasol Cream;",
"     </li>",
"     <li>",
"      Mylan-Clobetasol Ointment;",
"     </li>",
"     <li>",
"      Mylan-Clobetasol Scalp Application;",
"     </li>",
"     <li>",
"      Novo-Clobetasol;",
"     </li>",
"     <li>",
"      PMS-Clobetasol;",
"     </li>",
"     <li>",
"      ratio-Clobetasol;",
"     </li>",
"     <li>",
"      Taro-Clobetasol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenal Corticosteroid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"      see \"Clobetasol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Use the smallest amount for the shortest period of time to avoid HPA suppression; discontinue therapy when control is achieved; reassess diagnosis if no improvement is seen within 2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &lt;12 years: Use not recommended (high risk of systemic adverse effects, eg, HPA axis suppression, Cushing's syndrome)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Steroid-responsive dermatoses:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cream, emollient cream, gel, lotion, ointment: Apply sparingly twice daily for up to 2 weeks; maximum dose: 50 g/week or 50 mL/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Foam, solution: Apply sparingly to affected area of scalp twice daily for up to 2 weeks; maximum dose: 50 g/week or 50 mL/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild to moderate plaque-type psoriasis of nonscalp areas: Foam: Apply sparingly to affected area twice daily for up to 2 weeks; maximum dose: 50 g/week; do not apply to face or intertriginous areas",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate to severe plaque-type psoriasis: Emollient cream: Apply sparingly twice daily for up to 2 weeks; if response is not adequate, may be used for up to 2 more weeks if application is &lt;10% of body surface area; use with caution; maximum dose: 50 g/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;18 years and Adults: Moderate to severe plaque-type psoriasis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lotion: Apply sparingly twice daily for up to 2 weeks; if response is not adequate, may be used for up to 2 more weeks if application is &lt;10% of body surface area; use with caution; maximum dose: 50 mL/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Spray: Apply sparingly twice daily for up to 2 weeks; if response is not adequate, may be used for up to 2 more weeks, but use should be limited to skin lesions that have not sufficiently improved; maximum dose: 50 g (59 mL) per week",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F152816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, topical, as propionate: 0.05% (50 g, 100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Olux-E&trade;: 0.05% (50 g, 100 g) [chlorofluorocarbon free, ethanol free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Olux&reg;: 0.05% (50 g, 100 g) [chlorofluorocarbon free; contains ethanol 60%; for scalp application]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as propionate: 0.05% (15 g, 30 g, 45 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Temovate&reg;: 0.05% (30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as propionate [emollient-based]: 0.05% (15 g, 30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Temovate E&reg;: 0.05% (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical, as propionate: 0.05% (15 g, 30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Temovate&reg;: 0.05% (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical, as propionate: 0.05% (59 mL, 118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clobex&reg;: 0.05% (30 mL, 59 mL, 118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as propionate: 0.05% (15 g, 30 g, 45 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cormax&reg;: 0.05% (15 g [DSC], 45 g [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Temovate&reg;: 0.05% (15 g, 30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo, topical, as propionate: 0.05% (118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clobex&reg;: 0.05% (118 mL) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical, as propionate [for scalp application]: 0.05% (25 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cormax&reg;: 0.05% (25 mL [DSC], 50 mL) [contains isopropyl alcohol 40%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Temovate&reg;: 0.05% (50 mL) [contains isopropyl alcohol 39.3%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical, as propionate [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clobex&reg;: 0.05% (59 mL, 125 mL) [contains ethanol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F152801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes spray",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: All products: Apply sparingly to clean dry skin of affected area, gently rub in until disappears; do not use on open skin; do not apply to face, underarms, or groin area; avoid contact with eyes and lips; do not occlude affected area; wash hands after applying",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Foam: Turn can upside down and spray a small amount (maximum: 1",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     capful or about the size of a golf ball) of foam into the cap, other cool surface, or to affected area. If the can is warm or foam is runny, place can under cold, running water. If fingers are warm, rinse with cool water and dry prior to handling (foam will melt on contact with warm skin). Massage foam into affected area.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1051749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, emollient cream, ointment: Store at room temperature, between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Do not refrigerate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Foam: Store at room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); do not expose to heat or temperatures &gt;49&deg;C (120&deg;F). Can is pressurized; do not puncture or incinerate. Contents are flammable; avoid flame, fire, or smoking during and immediately after application.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel: Store between 2&deg;C to 30&deg;C (36&deg;F to 86&deg;F)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion: Store at room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Do not freeze.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution: Do not use near open flame.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cormax&reg; scalp application: Store at room temperature between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not refrigerate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Temovate&reg; scalp application: Store between 4&deg;C to 25&deg;C (39&deg;F to 77&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Spray: Store at controlled room temperature; do not refrigerate or freeze; do not store at &gt;30&deg;C; spray is flammable; avoid heat, do not use near open flame",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term relief of inflammation and pruritus associated with corticosteroid-responsive dermatoses",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3196820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Clobex [U.S., Canada, and multiple international markets] may be confused with Codex brand name for",
"       <i>",
"        Saccharomyces boulardii",
"       </i>",
"       [Italy]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cloderm: Brand name for clobetasol [China, India, Malaysia, Singapore, Thailand], but also brand name for alclometasone [Indonesia]; clocortolone [U.S., Canada]; clotrimazole [Germany]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F152850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May depend upon formulation used, length of application, surface area covered, and the use of occlusive dressings.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Central nervous system: Intracranial hypertension (systemic effect reported in children treated with topical corticosteroids)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Adrenal suppression, Cushing's syndrome, hyperglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Application site: Burning, cracking/fissuring of the skin, dryness, erythema, folliculitis, irritation, numbness, pruritus, skin atrophy, stinging, telangiectasia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Glucosuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Effects reported with other high-potency topical steroids: Acneiform eruptions, allergic contact dermatitis, hypertrichosis, hypopigmentation, maceration of the skin, miliaria, perioral dermatitis, secondary infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clobetasol propionate, other corticosteroids, or any component; the solution for scalp application is also contraindicated for use in patients with primary scalp infections",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using higher than recommended doses; suppression of HPA axis, suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral, or hypercorticism (Cushing's syndrome) may occur. Discontinue treatment if local irritation develops. Use appropriate antibacterial or antifungal agents to treat concomitant skin infections; discontinue clobetasol treatment if infection does not resolve promptly.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1051744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypothalamic-pituitary-adrenal (HPA) axis suppression may occur with topical clobetasol use, even at low doses; acute adrenal insufficiency may occur with abrupt withdrawal after long-term use or with stress; withdrawal or discontinuation should be done carefully; patients with HPA axis suppression may require increased doses of systemic glucocorticosteroids prior to, during, and after unusual stress (eg, surgery). Adverse systemic effects (including HPA axis suppression) may occur when topical steroids are used on large areas of the body, denuded areas, for prolonged periods of time, with an occlusive dressing, and/or in pediatric patients; infants and small children may be more susceptible to HPA axis suppression or other systemic toxicities due to a larger skin surface area to body mass ratio; use with caution in pediatric patients; due to the increased risk of HPA axis suppression and other systemic toxicities, the use of any clobetasol product for the treatment of steroid-responsive dermatoses is not recommended in children &lt;12 years of age; use of clobetasol lotion or spray for moderate to severe plaque-type psoriasis in children &lt;18 years is not recommended.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Do not use topical clobetasol for the treatment of rosacea or perioral dermatitis; do not apply to the face, groin, or axillae. Do not exceed maximum recommended dose or duration of therapy due to the potential development of HPA axis suppression.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F152809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F152811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F152824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Extensive use in pregnant women is not recommended. There are no adequate and well-controlled studies in pregnant women, however, teratogenic effects were observed in animal studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1051752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Assess HPA axis suppression in patients using potent topical steroids applied to a large surface area or to areas under occlusion (eg, ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not well defined topically; possesses anti-inflammatory, antipruritic, antiproliferative, vasoconstrictive, and immunosuppressive properties",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Percutaneous absorption varies and depends on many factors including vehicle used, integrity of epidermis, dose, and use of occlusive dressing; absorption is increased by occlusive dressings or with decreased integrity of skin (eg, inflammation or skin disease); gel has greater absorption than cream",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Drug and metabolites are excreted in urine and bile",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1051751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/34/13860?source=see_link\">",
"      see \"Clobetasol: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid contact with eyes and lips; do not apply to face, underarms, or groin area; do not bandage, cover, or wrap affected area unless directed by physician; wash hands after applying. Use only as prescribed and for the minimum amount of time required; do not use for longer than directed; notify physician if condition being treated persists or worsens; inform physician of use if surgery is to be considered.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1051761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Considered to be a super high potency topical corticosteroid; clobetasol is a prednisolone analog with a high level of glucocorticoid activity and slight degree of mineralocorticoid activity. Nine of 14 pediatric patients (12-17 years of age) with moderate to severe atopic dermatitis (involving &ge;20% BSA), who were treated with clobetasol lotion 0.05% twice daily for 2 weeks, developed adrenal suppression (versus 2 of 10 patients treated with the cream). Due to this high incidence of adrenal suppression, the lotion is not approved for this indication in children &lt;18 years of age.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12609 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-95F309B6B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_59_17333=[""].join("\n");
var outline_f16_59_17333=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152831\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152832\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051753\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051746\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152816\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152801\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051757\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051749\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051756\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3196820\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152850\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051760\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051745\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051744\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299062\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152809\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152811\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152824\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051752\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051743\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051759\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051751\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051761\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12609\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12609|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=related_link\">",
"      Clobetasol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/34/13860?source=related_link\">",
"      Clobetasol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_59_17334="Overview of conventional gynecologic laparoscopic surgery";
var content_f16_59_17334=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of conventional gynecologic laparoscopic surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/59/17334/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/59/17334/contributors\">",
"     Thomas G Stovall, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/59/17334/contributors\">",
"     William J Mann, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/59/17334/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/59/17334/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/59/17334/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/59/17334/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/59/17334/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laparoscope is as an essential diagnostic and therapeutic operative tool. The broader issues related to laparoscopy and the surgical techniques that are common to many gynecologic laparoscopic procedures will be reviewed here. Specific uses of laparoscopy are discussed in the individual topic reviews on each entity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15018?source=see_link\">",
"     \"Surgical sterilization of women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24583?source=see_link\">",
"     \"Laparoscopic surgery for ovulation induction in polycystic ovary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ROLE OF LAPAROSCOPY IN GYNECOLOGIC SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although commonly performed in patients with benign disease, laparoscopic surgery is also playing an expanding role in the management of gynecologic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17334/abstract/1\">",
"     1",
"    </a>",
"    ]. Laparoscopic surgical procedures are usually performed in an effort to replicate procedures that have been successful at laparotomy. Potential advantages of laparoscopy over laparotomy include shorter operative time (for some, but not all, procedures), smaller scar, faster recovery, decreased adhesion formation, and decreased cost [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17334/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 27 randomized clinical trials comparing operative laparoscopy to laparotomy for benign gynecological conditions found the overall risk of minor complications (eg, fever, wound or urinary tract infection) was lower in women undergoing laparoscopic procedures (RR 0.55, 95% CI 0.45-0.66) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17334/abstract/5\">",
"     5",
"    </a>",
"    ]. In comparison, both groups had the same risk of major complications, such as pulmonary embolus, transfusion, fistula formation, major additional unplanned surgery.",
"   </p>",
"   <p>",
"    However, just because a procedure can be performed using a laparoscope connected to a video monitor does not necessarily mean that it should be. As an example, the place for laparoscopically assisted vaginal hysterectomy, as opposed to traditional abdominal or vaginal hysterectomy, and the place of laparoscopic myomectomy versus abdominal myomectomy, are unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35401?source=see_link&amp;anchor=H14#H14\">",
"     \"Vaginal hysterectomy\", section on 'Laparoscopic assistance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8970?source=see_link&amp;anchor=H7666273#H7666273\">",
"     \"Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)\", section on 'Choosing the surgical approach for myomectomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8970?source=see_link\">",
"     \"Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREOPERATIVE ASSESSMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of prior abdominal surgery (eg, bowel surgery, umbilical hernia repair), disease (eg, appendicitis, pelvic inflammatory disease), or radiation therapy should be determined as this history is associated with intraabdominal adhesions and anatomic distortion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17334/abstract/6\">",
"     6",
"    </a>",
"    ]. The presence of ventral and umbilical hernias also needs to be noted to avoid needle or trocar insertion as these sites. The risk of bowel or vascular injury, as well as the need to convert to an open procedure, should be discussed with all patients, but particularly those with abnormal abdominal findings. Alternative methods that may make laparoscopic entry safer include use of the Hasson open approach, direct intraperitoneal open placement with a 5 millimeter trocar and laparoscope, use of Palmer's point in the left hypochondrium, or other alternative sites. A randomized trial found that routine mechanical bowel preparation before gynecologic laparoscopy did not facilitate surgery or decrease the incidence of complications, but was uncomfortable for the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17334/abstract/7\">",
"     7",
"    </a>",
"    ]. Antibiotic prophylaxis is not recommended as the frequency of wound infection is low [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17334/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Navel jewelry",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of navel jewelry, such as rings, is not uncommon. My preference is to have the patient remove the ring the day prior to the procedure and cleanse the umbilicus thoroughly. I also ask the patient not to replace the ring until I have examined her five to seven days postoperatively. An alternative approach is temporary removal of the jewelry and replacement with a nonmetallic spacer (eg, sterile plastic sutures or thin tubing) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17334/abstract/9\">",
"     9",
"    </a>",
"    ]. Postoperatively, most navel jewelry can be replaced after the skin of the laparoscopy incision has sealed (preferably after two or more days) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17334/abstract/10\">",
"     10",
"    </a>",
"    ]. Both the jewelry and skin site are disinfected prior to reinsertion. Antibiotics are not necessary and ointments should be avoided because they clog the piercing tract.",
"   </p>",
"   <p>",
"    Oral and nasal jewelry (eg, tongue and nose rings) can interfere with intubation during administration of general anesthesia and body piercing at any site can conduct electric current if electrosurgery is performed; therefore, caution should be exercised when such jewelry is in place [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17334/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. It is recommended that all metallic jewelry be removed to prevent complications, as well as loss of the jewelry [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17334/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/2/10282?source=see_link&amp;anchor=H17#H17\">",
"     \"Body piercing in adolescents and young adults\", section on 'Removal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATIENT POSITIONING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The woman is placed in a supine or dorsal lithotomy position. Another alternative is to position the patient supine with legs spread to allow access to the vagina.",
"   </p>",
"   <p>",
"    If the dorsal lithotomy position is used, the patient's legs are placed in Allen&reg; stirrups. The knees should be deflexed to avoid stretching of the femoral nerve. The buttocks should be a few centimeters beyond the edge of the table to allow uterine manipulation. Operator preference and the scope of the intended procedure determine the optimal position.",
"   </p>",
"   <p>",
"    A bladder catheter is useful to avoid bladder distension, which increases the risk of bladder perforation and may obscure the operative field.",
"   </p>",
"   <p>",
"    After insertion of trocars, the patient is tilted into Trendelenburg's position (20- to 45-degree angle) to assist with displacement of the bowel from the pelvis. Shoulder restraints can cause compression of the brachial plexus if the patient is placed in deep Trendelenburg; this may be avoided by placing the restraints laterally on the acromioclavicular joint.",
"   </p>",
"   <p>",
"    Prevention of nerve injury due to patient positioning is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3129?source=see_link&amp;anchor=H22#H22\">",
"     \"Nerve injury associated with pelvic surgery\", section on 'Avoid patient malposition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INSTRUMENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all instruments available for laparotomy are now available for use at laparoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38440?source=see_link\">",
"     \"Surgical instruments for gynecologic surgery\"",
"    </a>",
"    .) However, because the instruments must fit through a 3- to 20-mm port and must be of sufficient length to reach the pelvis, specialized instruments have been devised. Virtually all instruments are available in a reusable, disposable, or hybrid form (part of the instrument is disposable and part is reusable). Disposable instruments are typically less cost effective, although they have the advantage of always being available, and the cutting edges are always sharp. Situations occasionally arise where a laparotomy instrument may be used directly through a lower portal. There are also techniques evolving in which the operator's sleeved hand may be introduced into the abdomen during the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Telescopes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Telescopes for laparoscopy are of two basic types, those with and those without an operative channel (",
"    <a class=\"graphic graphic_picture graphicRef52659 \" href=\"UTD.htm?39/38/40559\">",
"     picture 1",
"    </a>",
"    ). They range in size from 3 to 12 mm and have straight or angled lenses. The 0-degree lens provides a panoramic view of the pelvis and is preferred by most gynecologic surgeons, although angled 30-, 45-, and 135-degree lenses assist in evaluating the anterior abdominal wall or working around masses. Almost all of the telescopes used today are rod lense laparoscopes, which do not use fiber bundles unless the instrument is flexible or semi rigid. The choice of telescope is generally based upon operator preference.",
"   </p>",
"   <p>",
"    Flexible telescopes have also been introduced.",
"   </p>",
"   <p>",
"    Telescope warmers are used by some surgeons to reduce fogging during the procedure. Antifog solutions are also very successful. Three-dimensional systems are under evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Light source",
"    </span>",
"    &nbsp;&mdash;&nbsp;The application of fiberoptic technology has allowed a greater intensity of light to be delivered to the laparoscope and into the abdomen. Light transmission is improved as the number of fibers, size of the cable, and the power of the light source all increase. In contrast, illumination is reduced at each junction in the system, such as the use of a beam splitter or when there is an operating port. Transmission is also reduced if the optic cables are damaged or broken.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17048742\">",
"    <span class=\"h3\">",
"     Video",
"    </span>",
"    &nbsp;&mdash;&nbsp;Video monitors allow the surgeon and the remainder of the operating team to visualize the procedure. The camera is attached to the telescope and white-balanced before being placed into the abdominal cavity. Earlier cameras used beam splitters to allow the surgeon to look down the telescope as well as operate from the video monitor. This is really not necessary and decreases the quality of the picture obtained.",
"   </p>",
"   <p>",
"    Generally, two monitors are used for pelvic laparoscopy, one placed within the view of each surgeon. Whether a permanent videotaped copy of the procedure should be made is controversial. Some surgeons prefer to provide a copy to the patient while others believe that it is not necessary and potentially increases the surgeon's liability. Photos may also be taken.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17048863\">",
"    <span class=\"h2\">",
"     Laparoscopic entry and insufflation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic entry can be performed with a closed (Veress needle) or open technique (Hasson technique). Once pneumoperitoneum has been established, a trocar is placed to pass the camera and instruments. A variety of trocars are available. A detailed discussion of techniques for laparoscopic entry can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=see_link\">",
"     \"Abdominal access techniques used in laparoscopic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Uterine cannula",
"    </span>",
"    &nbsp;&mdash;&nbsp;The uterine cannula is used to manipulate the uterus and thereby facilitate visualization of and access to pelvic structures. Most cannulas also permit injection of a dye solution (chromopertubation) to assess tubal patency. A variety of uterine manipulators are available. The most widely used are the Cohen cannula (",
"    <a class=\"graphic graphic_picture graphicRef78608 \" href=\"UTD.htm?33/27/34239\">",
"     picture 2",
"    </a>",
"    ) and the Hulka uterine manipulator (",
"    <a class=\"graphic graphic_picture graphicRef72152 \" href=\"UTD.htm?27/38/28256\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A uterine cannula should not be used when:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The uterus is absent",
"     </li>",
"     <li>",
"      Anomalies exist that prevent exposure of or access to the cervix",
"     </li>",
"     <li>",
"      The woman is a prepubescent female",
"     </li>",
"     <li>",
"      An intrauterine pregnancy is suspected",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A sponge stick, or examining hand, may be positioned in the vagina in the absence of the uterus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17048846\">",
"    <span class=\"h2\">",
"     Grasping instruments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Grasping forceps have been designed for tissue manipulation. Some are broad and flat, while others are finer and made for delicate tissue handling (",
"    <a class=\"graphic graphic_picture graphicRef76349 \" href=\"UTD.htm?7/45/7888\">",
"     picture 4",
"    </a>",
"    ). Toothed forceps are used to put traction on tissue that is to be removed, such as for grasping ovarian cysts and leiomyomas. Forceps with pointed ends are used for tissue dissection and surgical plane development (",
"    <a class=\"graphic graphic_picture graphicRef79221 \" href=\"UTD.htm?38/16/39182\">",
"     picture 5",
"    </a>",
"    ). Ratcheted and non-ratcheted varieties exist.",
"   </p>",
"   <p>",
"    Atraumatic tissue-grasping instruments have double action and curved jaws and are operated by either a scissors or a spring handle. A disposable Babcock-type atraumatic grasper with a ratcheted scissors handle can be particularly useful in handling adnexal structures. Biopsy forceps may double as grasping instruments, but can be traumatic to the tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cutting and coagulating equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scissors and other instruments for dissection are available. Many of these use electrosurgical, ultrasonic, or laser energy. These devices are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14984?source=see_link&amp;anchor=H3#H3\">",
"     \"Devices for dissection and hemostasis in laparoscopic surgery\", section on 'Devices for hemostasis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37737?source=see_link\">",
"     \"Overview of electrosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Suturing and stapling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various instruments are available for laparoscopic suturing and stapling. These devices are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14984?source=see_link&amp;anchor=H5#H5\">",
"     \"Devices for dissection and hemostasis in laparoscopic surgery\", section on 'Suture ligation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14984?source=see_link&amp;anchor=H6#H6\">",
"     \"Devices for dissection and hemostasis in laparoscopic surgery\", section on 'Surgical staplers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Suction and irrigation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suction and irrigation are important for all types of laparoscopic surgery. Irrigation is used for removal of char or for visualization when bleeding is encountered. Irrigation can also be used for hydrodissection and creation of tissue planes.",
"   </p>",
"   <p>",
"    A variety of suction instruments have been designed that are adequate for removal of irrigation fluid, or intraperitoneal air and smoke. A large-bore device is best for removal of blood clots when brisk bleeding is encountered and also for passing laser fiber.",
"    <span class=\"nowrap\">",
"     Suction/irrigation",
"    </span>",
"    devices offer a combination of cautery or needle tip electrodes (",
"    <a class=\"graphic graphic_picture graphicRef77450 \" href=\"UTD.htm?15/61/16338\">",
"     picture 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Tissue removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue morcellators are used for reduction of large masses into smaller fragments to assist with tissue removal. Both manual and automatic morcellators are available, the latter are costly but are very effective and save time when large amounts of tissue are to be removed.",
"   </p>",
"   <p>",
"    Currently, there are several good alternatives available for the surgeon attempting to remove large volumes of tissue without increasing incision size dramatically. There is a reusable morcellator handpiece with a mechanical drive generator (Storz, Inc), a disposable handpiece with a generator product (Morcellex&trade;), a disposable handpiece with a battery powered drive that completes the hand-operated system (Twincut&trade;), and a disposable handpiece with grasper that runs off of the PK generator using bipolar radiofrequency energy (SWORD&trade;). There are no high quality data comparing among these instruments.",
"   </p>",
"   <p>",
"    Tissue bags can be used for tissue isolation before or after morcellation (",
"    <a class=\"graphic graphic_picture graphicRef57113 \" href=\"UTD.htm?28/26/29102\">",
"     picture 7",
"    </a>",
"    ). Large cysts can be aspirated after placing them in the bag, taking care not to puncture the bag or spill its contents. The bags can be removed through a secondary trocar or through the infraumbilical trocar insertion site after the trocar has been removed.",
"   </p>",
"   <p>",
"    Tissue dilators are used for stretching a 10-mm port to a 20-mm port. This technique can be very helpful for tissue removal. A colpotomy incision can also be an effective alternative to tissue removal through a secondary trocar; colpotomy is especially useful for removal of larger tissue pieces or ovarian masses. A corkscrew device is screwed into myomas to remove them through a colpotomy incision or through a minilaparotomy incision. Finally, one can enlarge a port incision to remove tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of laparoscopic surgery and their management are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7415?source=see_link\">",
"     \"Complications of gynecologic laparoscopic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     CREDENTIALING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Credentialing (ie, approving a surgeon to perform a particular surgical procedure) is not new and has been discussed in a variety of forums since laparoscopy became commonplace. The purpose is to ensure high quality health care provided by competent surgeons. Credentialing involves a review of the procedures performed, the quality of the procedures, as well as the indications and patient selection criteria that the surgeon. Interest in credentialing comes from residency programs, malpractice insurance companies, third-party payers, government health agencies, and consumer advocacy groups.",
"   </p>",
"   <p>",
"    Numerous pitfalls can occur during the credentialing process. As an example: Who is the first to be credentialed? How often will it take place? Will the credentialing be procedure specific or technique driven? What will be done with the surgeon who is currently performing the procedures but does not pass the credentialing process? What are the acceptable rates of complications for the various operative procedures? The Society of Reproductive Surgeons has published credentialing guidelines for laparoscopic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17334/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Stratification of laparoscopic procedures has been proposed by the Society of Reproductive Surgeons and the American Fertility Society. These guidelines can be used as a resource for individual facilities to use in establishing their own quality assurance and credentialing processes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H753520\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laparoscopic surgery has several advantages over laparotomy, including decreases in duration of hospital stay, recovery time, and minor complications. However, the risk of major complications (pulmonary embolus, transfusion, fistula formation, major additional unplanned surgery) is the same for the two surgical approaches. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Role of laparoscopy in gynecologic surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preoperative evaluation prior to laparoscopy includes assessment of adhesive disease and other conditions that may alter the anatomy of the abdominal wall and peritoneal cavity (eg, umbilical hernia, appendicitis, pelvic inflammatory disease). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The standard patient positions for laparoscopy are supine or dorsal lithotomy. If the dorsal lithotomy position is used, the patient's legs are placed in stirrups. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Patient positioning'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Almost all instruments available for laparotomy are now available for use at laparoscopy. Instruments that are particular to laparoscopy include the telescope (camera), instruments for laparoscopic entry, the uterine cannula to manipulate the uterus, and bags and morcellators used for tissue removal. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Instrumentation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17334/abstract/1\">",
"      Schlaerth AC, Abu-Rustum NR. Role of minimally invasive surgery in gynecologic cancers. Oncologist 2006; 11:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17334/abstract/2\">",
"      Azziz, R, Steinkampf, MP, Murphy, A. Postoperative recuperation: relation to the extent of endoscopic surgery. Fertil Steril 1989; 5:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17334/abstract/3\">",
"      Lundorff P, Hahlin M, K&auml;llfelt B, et al. Adhesion formation after laparoscopic surgery in tubal pregnancy: a randomized trial versus laparotomy. Fertil Steril 1991; 55:911.",
"     </a>",
"    </li>",
"    <li>",
"     Levine, RL. Economic impact of pelviscopic surgery.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17334/abstract/5\">",
"      Chapron C, Fauconnier A, Goffinet F, et al. Laparoscopic surgery is not inherently dangerous for patients presenting with benign gynaecologic pathology. Results of a meta-analysis. Hum Reprod 2002; 17:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17334/abstract/6\">",
"      Chi DS, Abu-Rustum NR, Sonoda Y, et al. Ten-year experience with laparoscopy on a gynecologic oncology service: analysis of risk factors for complications and conversion to laparotomy. Am J Obstet Gynecol 2004; 191:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17334/abstract/7\">",
"      Muzii L, Bellati F, Zullo MA, et al. Mechanical bowel preparation before gynecologic laparoscopy: a randomized, single-blind, controlled trial. Fertil Steril 2006; 85:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17334/abstract/8\">",
"      ACOG Committee on Practice Bulletins. ACOG Practice Bulletin No. 74. Antibiotic prophylaxis for gynecologic procedures. Obstet Gynecol 2006; 108:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17334/abstract/9\">",
"      Muensterer OJ. Temporary removal of navel piercing jewelry for surgery and imaging studies. Pediatrics 2004; 114:e384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17334/abstract/10\">",
"      Jacobs VR, Morrison JE Jr, Paepke S, Kiechle M. Body piercing affecting laparoscopy: perioperative precautions. J Am Assoc Gynecol Laparosc 2004; 11:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17334/abstract/11\">",
"      Oyos TL. Intubation sequence for patient presenting with tongue ring. Anesthesiology 1998; 88:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17334/abstract/12\">",
"      Rosenberg AD, Young M, Bernstein RL, Albert DB. Tongue rings: just say no. Anesthesiology 1998; 89:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17334/abstract/13\">",
"      Keye WR Jr. Hitting a moving target: credentialing the endoscopic surgeon. Fertil Steril 1994; 62:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17334/abstract/14\">",
"      Guidelines for attaining privileges in gynecologic operative endoscopy. Society for Reproductive Surgeons. American Fertility Society. Fertil Steril 1994; 62:1118.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3269 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-3C09538E6E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_59_17334=[""].join("\n");
var outline_f16_59_17334=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H753520\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ROLE OF LAPAROSCOPY IN GYNECOLOGIC SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREOPERATIVE ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Navel jewelry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATIENT POSITIONING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INSTRUMENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Telescopes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Light source",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17048742\">",
"      - Video",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17048863\">",
"      Laparoscopic entry and insufflation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Uterine cannula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17048846\">",
"      Grasping instruments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cutting and coagulating equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Suturing and stapling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Suction and irrigation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Tissue removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      CREDENTIALING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H753520\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3269\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3269|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/38/40559\" title=\"picture 1\">",
"      Types of laparoscopes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/27/34239\" title=\"picture 2\">",
"      Cohen cannula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/38/28256\" title=\"picture 3\">",
"      Hulka uterine manipulator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/45/7888\" title=\"picture 4\">",
"      Laparoscopy surgery instruments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/16/39182\" title=\"picture 5\">",
"      Dissecting instrument",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/61/16338\" title=\"picture 6\">",
"      Suction irrigator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/26/29102\" title=\"picture 7\">",
"      Tissue bag for laparoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=related_link\">",
"      Abdominal access techniques used in laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/2/10282?source=related_link\">",
"      Body piercing in adolescents and young adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7415?source=related_link\">",
"      Complications of gynecologic laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14984?source=related_link\">",
"      Devices for dissection and hemostasis in laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8970?source=related_link\">",
"      Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24583?source=related_link\">",
"      Laparoscopic surgery for ovulation induction in polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3129?source=related_link\">",
"      Nerve injury associated with pelvic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37737?source=related_link\">",
"      Overview of electrosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38440?source=related_link\">",
"      Surgical instruments for gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15018?source=related_link\">",
"      Surgical sterilization of women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35401?source=related_link\">",
"      Vaginal hysterectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_59_17335="Antiprotozoal therapies";
var content_f16_59_17335=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antiprotozoal therapies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/59/17335/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/59/17335/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/59/17335/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/59/17335/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/59/17335/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/59/17335/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/59/17335/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protozoan parasites belong to four distinct groups: the amebae, the flagellates, the ciliates, and the sporozoa. Protozoa are single celled organisms and replicate by various mechanisms within the infected host. The mechanisms of action of the various agents used to treat protozoan parasites are relatively poorly understood [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17335/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States the antiprotozoal drugs melarsoprol, nifurtimox, sodium stibogluconate, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/50/30498?source=see_link\">",
"     suramin",
"    </a>",
"    are available through the Centers for Disease Control and Prevention Drug Service, Atlanta, GA 30333 (telephone 404-639-2888).",
"   </p>",
"   <p>",
"    Agents with activity against protozoal parasites will be reviewed here (",
"    <a class=\"graphic graphic_table graphicRef86520 \" href=\"UTD.htm?41/57/42898\">",
"     table 1",
"    </a>",
"    ); their use for treatment of specific protozoal infections is discussed in detail separately. Antimalarial agents are discussed in detail separately, as are agents with activity against helminths. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20809?source=see_link\">",
"     \"Antimalarial drugs: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23221?source=see_link\">",
"     \"Anthelminthic therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ALBENDAZOLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     Albendazole",
"    </a>",
"    binds to tubulin and affects cytoskeletal microtubules and is a well established therapy treatment of helminthic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17335/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23221?source=see_link\">",
"     \"Anthelminthic therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     Albendazole",
"    </a>",
"    also has activity against some protozoan infections including most microsporidial species, particularly Encephalitozoon infections. However it is not as active against E. bieneusi [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17335/abstract/3-10\">",
"     3-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16089?source=see_link\">",
"     \"Microsporidiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Absorption of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    is enhanced by taking it with fatty meals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ATOVAQUONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     Atovaquone",
"    </a>",
"    is a hydroxynaphthoquinone agent active against several protozoan parasites [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17335/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the treatment of Pneumocystis jirovecii (formerly carinii) pneumonia (PCP),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    is well tolerated but less effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX). Atovaquone is an alternative agent for prophylaxis against PCP for patients who are unable to tolerate TMP-SMX. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=see_link\">",
"     \"Treatment of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2889?source=see_link\">",
"     \"Prophylaxis against Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     Atovaquone",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    is an alternative agent for treatment and long-term maintenance therapy of toxoplasma encephalitis in AIDS patients intolerant of sulfonamides. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=see_link\">",
"     \"Toxoplasmosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"     Atovaquone-proguanil",
"    </a>",
"    may be used for malaria chemoprophylaxis and is also effective in the treatment of P. falciparum malaria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20809?source=see_link\">",
"     \"Antimalarial drugs: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     Atovaquone",
"    </a>",
"    -azithromycin may be used for treatment of babesiosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39321?source=see_link\">",
"     \"Clinical manifestations, diagnosis, treatment, and prevention of babesiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     Atovaquone",
"    </a>",
"    suspension is twice as well absorbed as the tablet form, and consumption of atovaquone with a fatty meal enhances absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17335/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     BENZNIDAZOLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benznidazole is a nitroimidazole derivative with activity against T. cruzi trypomastigotes and amastigotes. Side effects include rash, nausea, and peripheral neuritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14356?source=see_link\">",
"     \"Antitrypanosomal drug therapy for Chagas disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EFLORNITHINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37652?source=see_link\">",
"     Eflornithine",
"    </a>",
"    inhibits parasite growth by selective and irreversible inhibition of ornithine carboxylase, an enzyme required for cellular proliferation and differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17335/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. It is effective in the early and late central nervous system stage of infections with Trypanosoma brucei gambiense but not T. b. rhodesiense. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38681?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of African trypanosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Frequent side effects include diarrhea, anemia, leukopenia, and hair loss. Supplies are limited and the drug is available only from the World Health Organization (WHO).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     FUMAGILLIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fumagillin is an antibiotic released by Aspergillus fumigatus. The mechanism of action of fumagillin has not been established, but the drug can suppress proliferation of microsporidia in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17335/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical fumagillin therapy has been successful in several cases of microsporidial keratoconjunctivitis in patients with AIDS. Fumagillin has also been used to treat intestinal E. bieneusi infections in immunocompromised patients; neutropenia and thrombocytopenia are common complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16089?source=see_link\">",
"     \"Microsporidiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     FURAZOLIDONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Furazolidone is a nitrofuran derivative used as an alternative drug for giardiasis. Adverse effects include nausea, vomiting, and allergic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17335/abstract/16\">",
"     16",
"    </a>",
"    ]. The drug is a monoamine oxidase inhibitor and also causes a disulfiram-like reaction when taken with alcohol. Furazolidone is not bitter (unlike other drugs for giardiasis) and is available in a liquid form useful for young children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6424?source=see_link\">",
"     \"Treatment and prevention of giardiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     IODOQUINOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/38/21091?source=see_link\">",
"     Iodoquinol",
"    </a>",
"    is a halogenated oxyquinolone used for treatment of noninvasive amebiasis and Dientamoeba fragilis and as an alternative for Balantidium coli infection. Adverse effects are uncommon; optic neuritis has been observed when high doses are administered for a prolonged period [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17335/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33671?source=see_link\">",
"     \"Intestinal Entamoeba histolytica amebiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35237?source=see_link\">",
"     \"Dientamoeba fragilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32834?source=see_link\">",
"     \"Balantidium coli infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MELARSOPROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melarsoprol is a trivalent arsenical compound used to treat late-stage African trypanosomiasis involving the CNS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17335/abstract/18\">",
"     18",
"    </a>",
"    ]. Melarsoprol appears to act by binding to essential thiol groups of trypanosomes, preventing trophozoite multiplication [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17335/abstract/13,19,20\">",
"     13,19,20",
"    </a>",
"    ]. Severe adverse effects are common, including myocarditis, encephalopathy, and hypersensitivity reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17335/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38681?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of African trypanosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     METRONIDAZOLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    is a 5-nitroimidazole with potent activity against several protozoa including Entamoeba histolytica, Giardia lamblia, and Trichomonas vaginalis. Metronidazole is the drug of choice for giardiasis, intestinal, and extraintestinal amebiasis and trichomoniasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33671?source=see_link\">",
"     \"Intestinal Entamoeba histolytica amebiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33031?source=see_link\">",
"     \"Extraintestinal Entamoeba histolytica amebiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6424?source=see_link\">",
"     \"Treatment and prevention of giardiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1881?source=see_link\">",
"     \"Trichomonas vaginalis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    is generally well tolerated; adverse effects include mild abdominal pain, headache, nausea, and metallic taste. It produces a disulfiram-like reaction when taken with alcohol. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31817?source=see_link\">",
"     \"Metronidazole: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     NIFURTIMOX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nifurtimox is a synthetic nitrofuran compound for treatment of acute Trypanosoma cruzi infection. The drug has little effect in chronic Chagas disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16742?source=see_link\">",
"     \"Gastrointestinal Chagas disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16184?source=see_link&amp;anchor=H372251532#H372251532\">",
"     \"Treatment and prognosis of Chagas heart disease\", section on 'T.cruzi infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nifurtimox can be used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37652?source=see_link\">",
"     eflornithine",
"    </a>",
"    or melarsoprol for treatment of African trypanosomiasis due to T. b. gambiense. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38681?source=see_link&amp;anchor=H4239238#H4239238\">",
"     \"Clinical manifestations, diagnosis, and treatment of African trypanosomiasis\", section on 'Nifurtimox combination therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adverse reactions are common and dose-dependent, including nausea, vomiting, insomnia, headache, vertigo, tremor, paresthesias, and convulsions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17335/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     NITAZOXANIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     Nitazoxanide",
"    </a>",
"    is a nitrothiazolyl-salicylamide derivative useful for treatment diarrhea due to Cryptosporidium parvum in children and for the treatment of giardiasis in children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17335/abstract/22\">",
"     22",
"    </a>",
"    ]. It is generally well tolerated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6424?source=see_link\">",
"     \"Treatment and prevention of giardiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     Nitazoxanide",
"    </a>",
"    has not been shown to be more effective than placebo in HIV-infected patients; prolonged therapy at higher doses may be required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13961?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PAROMOMYCIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"     Paromomycin",
"    </a>",
"    is an oral, poorly-absorbed aminoglycoside. It is used as a secondary drug for treatment of noninvasive amebiasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33671?source=see_link\">",
"     \"Intestinal Entamoeba histolytica amebiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It may also be used utilized the treatment of giardiasis during pregnancy when the disease is not severe enough to require definitive therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or quinacrine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6424?source=see_link\">",
"     \"Treatment and prevention of giardiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PENTAMIDINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     Pentamidine",
"    </a>",
"    isethionate is an aromatic diamine compound active against Pneumocystis and several protozoal pathogens including Leishmanii spp. and T. b. gambiense [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17335/abstract/23\">",
"     23",
"    </a>",
"    ]. Adverse reactions of parenteral pentamidine are common, including reversible nephrotoxicity, acute hypotension, pancreatitis, hypoglycemia, cardiac arrhythmias, blood dyscrasias, and sterile abscesses at the injection site [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17335/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Aerosolized pentamidine used for the prophylaxis of PCP in susceptible patients is associated with local adverse effects, including sore throat, oral paresthesias, metallic taste, cough, and bronchospasm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PYRIMETHAMINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     Pyrimethamine",
"    </a>",
"    -sulfadiazine is used in the treatment of toxoplasmosis. The high doses required for this treatment often result in significant folate deficiency, requiring folinic acid replacement. Abdominal symptoms and rashes are also common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=see_link\">",
"     \"Toxoplasmosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     Pyrimethamine",
"    </a>",
"    -dapsone is used for prophylaxis of PCP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=see_link\">",
"     \"Treatment of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     Pyrimethamine",
"    </a>",
"    is effective for acute treatment and maintenance suppression of Isospora belli infections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17335/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30405?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Cystoisospora infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     QUINACRINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quinacrine is an acridine dye with activity against giardiasis. It is well absorbed and may impart a yellow color to the urine and rarely to the skin or sclerae. Adverse effects include headache, dizziness, vomiting, diarrhea, and, less commonly, psychotic episodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SPIRAMYCIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/18/14628?source=see_link\">",
"     Spiramycin",
"    </a>",
"    has activity against toxoplasmosis and is an alternative to antifolates. In the setting of intrauterine infection spiramycin is administered throughout pregnancy until delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=see_link\">",
"     \"Toxoplasmosis and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SODIUM STIBOGLUCONATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sodium stibogluconate (sodium antimony gluconate, Pentostam&reg;) is a pentavalent antimonial parenteral solution used in the treatment of leishmaniasis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17335/abstract/27\">",
"     27",
"    </a>",
"    ]. Its mechanism of action is unknown. Adverse effects include muscle pain, joint stiffness, nausea, vomiting, and less commonly rash, cardiac, or hepatic toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43625?source=see_link\">",
"     \"Treatment of visceral leishmaniasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SURAMIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/50/30498?source=see_link\">",
"     Suramin",
"    </a>",
"    is a polysulfonated naphthylamine derivative of urea. The mechanism of action is not fully understood; it is thought to act by inhibition of enzymes associated with DNA metabolism and protein synthesis in trypanosomal parasites [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17335/abstract/19,28\">",
"     19,28",
"    </a>",
"    ]. Suramin is used for treating the early stage of East African trypanosomiasis due to T. b. rhodesiense. It must be given intravenously and is excreted very slowly. Adverse effects are common and can be severe, including cutaneous eruptions, vomiting, paresthesias, photophobia, peripheral neuropathy, anaphylaxis, and renal damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38681?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of African trypanosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TETRACYCLINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     Tetracycline",
"    </a>",
"    has activity against Balantidium coli and Dientamoeba fragilis enteric infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32834?source=see_link\">",
"     \"Balantidium coli infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35237?source=see_link\">",
"     \"Dientamoeba fragilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TINIDAZOLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"     Tinidazole",
"    </a>",
"    has activity against amebiasis, giardiasis, and vaginal trichomoniasis and may be better tolerated than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33671?source=see_link\">",
"     \"Intestinal Entamoeba histolytica amebiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33031?source=see_link\">",
"     \"Extraintestinal Entamoeba histolytica amebiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6424?source=see_link\">",
"     \"Treatment and prevention of giardiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1881?source=see_link\">",
"     \"Trichomonas vaginalis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TRIMETHOPRIM-SULFAMETHOXAZOLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) is the preferred treatment for PCP and is used for prophylaxis against this infection in immunocompromised patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=see_link\">",
"     \"Treatment of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TMP-SMX is effective in treating enteric infections with Isospora belli and is used as long-term maintenance therapy to prevent relapse in patients with AIDS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30405?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Cystoisospora infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TMP-SMX also has activity against enteric infection due to cyclospora. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31493?source=see_link\">",
"     \"Cyclospora infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adverse effects are primarily due to the sulfamethoxazole and include skin, liver, and bone marrow toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4205629\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antiprotozoal agents with activity against giardiasis include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"       nitazoxanide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"       tinidazole",
"      </a>",
"      , furazolidone, and quinacrine. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Metronidazole'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Nitazoxanide'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Tinidazole'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Furazolidone'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Quinacrine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiprotozoal agents with activity against pneumocystis include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"       atovaquone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"       pentamidine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      -dapsone. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Trimethoprim-sulfamethoxazole'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Atovaquone'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Pentamidine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Pyrimethamine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiprotozoal agents with activity against amebiasis include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"       tinidazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"       paromomycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/38/21091?source=see_link\">",
"       iodoquinol",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Metronidazole'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Tinidazole'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Paromomycin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Iodoquinol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       Tetracycline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/38/21091?source=see_link\">",
"       iodoquinol",
"      </a>",
"      have activity against both Dientamoeba fragilis and Balantidium coli. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Tetracycline'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Iodoquinol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of antiprotozoal therapies for treatment of specific protozoal infections is discussed in detail separately. (See related topics.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/1\">",
"      Drugs for Parasitic Infections. Treat Guidel Med Lett 2010; 8 (suppl):e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/2\">",
"      Lacey E. Mode of action of benzimidazoles. Parasitol Today 1990; 6:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/3\">",
"      Blanshard C, Ellis DS, Tovey DG, et al. Treatment of intestinal microsporidiosis with albendazole in patients with AIDS. AIDS 1992; 6:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/4\">",
"      Molina JM, Oksenhendler E, Beauvais B, et al. Disseminated microsporidiosis due to Septata intestinalis in patients with AIDS: clinical features and response to albendazole therapy. J Infect Dis 1995; 171:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/5\">",
"      Weber R, Sauer B, Spycher MA, et al. Detection of Septata intestinalis in stool specimens and coprodiagnostic monitoring of successful treatment with albendazole. Clin Infect Dis 1994; 19:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/6\">",
"      Dieterich DT, Lew EA, Kotler DP, et al. Treatment with albendazole for intestinal disease due to Enterocytozoon bieneusi in patients with AIDS. J Infect Dis 1994; 169:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/7\">",
"      Asmuth DM, DeGirolami PC, Federman M, et al. Clinical features of microsporidiosis in patients with AIDS. Clin Infect Dis 1994; 18:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/8\">",
"      Molina JM, Chastang C, Goguel J, et al. Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: a randomized double-blind controlled trial. J Infect Dis 1998; 177:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/9\">",
"      Leder K, Ryan N, Spelman D, Crowe SM. Microsporidial disease in HIV-infected patients: a report of 42 patients and review of the literature. Scand J Infect Dis 1998; 30:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/10\">",
"      Conteas CN, Berlin OG, Speck CE, et al. Modification of the clinical course of intestinal microsporidiosis in acquired immunodeficiency syndrome patients by immune status and anti-human immunodeficiency virus therapy. Am J Trop Med Hyg 1998; 58:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/11\">",
"      Haile LG, Flaherty JF. Atovaquone: a review. Ann Pharmacother 1993; 27:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/12\">",
"      Dixon R, Pozniak AL, Watt HM, et al. Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients. Antimicrob Agents Chemother 1996; 40:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/13\">",
"      Denise H, Barrett MP. Uptake and mode of action of drugs used against sleeping sickness. Biochem Pharmacol 2001; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/14\">",
"      Kingsnorth AN. The chemotherapeutic potential of polyamine antimetabolites. Ann R Coll Surg Engl 1986; 68:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/15\">",
"      Beauvais B, Sarfati C, Challier S, Derouin F. In vitro model to assess effect of antimicrobial agents on Encephalitozoon cuniculi. Antimicrob Agents Chemother 1994; 38:2440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/16\">",
"      Altamirano A, Bondani A. Adverse reactions to furazolidone and other drugs. A comparative review. Scand J Gastroenterol Suppl 1989; 169:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/17\">",
"      American Academy of Pediatrics Committee on Drugs: Clioquinol (iodochlorhydroxyquin, vioform) and iodoquinol (diiodohydroxyquin): blindness and neuropathy. Pediatrics 1990; 86:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/18\">",
"      de Andrade AL, Zicker F, de Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996; 348:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/19\">",
"      Wang CC. Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annu Rev Pharmacol Toxicol 1995; 35:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/20\">",
"      Frayha GJ, Smyth JD, Gobert JG, Savel J. The mechanisms of action of antiprotozoal and anthelmintic drugs in man. Gen Pharmacol 1997; 28:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/21\">",
"      Castro JA, Diaz de Toranzo EG. Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas' disease). Biomed Environ Sci 1988; 1:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/22\">",
"      Nitazoxanide (Alinia)--a new anti-protozoal agent. Med Lett Drugs Ther 2003; 45:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/23\">",
"      Sands M, Kron MA, Brown RB. Pentamidine: a review. Rev Infect Dis 1985; 7:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/24\">",
"      O'Brien JG, Dong BJ, Coleman RL, et al. A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia. Clin Infect Dis 1997; 24:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/25\">",
"      Salamone FR, Cunha BA. Update on pentamidine for the treatment of Pneumocystis carinii pneumonia. Clin Pharm 1988; 7:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/26\">",
"      Weiss LM, Perlman DC, Sherman J, et al. Isospora belli infection: treatment with pyrimethamine. Ann Intern Med 1988; 109:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/27\">",
"      Herwaldt BL, Stokes SL, Juranek DD. American cutaneous leishmaniasis in U.S. travelers. Ann Intern Med 1993; 118:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17335/abstract/28\">",
"      P&eacute;pin J, Milord F. The treatment of human African trypanosomiasis. Adv Parasitol 1994; 33:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 489 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-519069B3B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_59_17335=[""].join("\n");
var outline_f16_59_17335=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4205629\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ALBENDAZOLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ATOVAQUONE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BENZNIDAZOLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EFLORNITHINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      FUMAGILLIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      FURAZOLIDONE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      IODOQUINOL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MELARSOPROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      METRONIDAZOLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      NIFURTIMOX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NITAZOXANIDE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PAROMOMYCIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PENTAMIDINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PYRIMETHAMINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      QUINACRINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SPIRAMYCIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SODIUM STIBOGLUCONATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SURAMIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TETRACYCLINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TINIDAZOLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TRIMETHOPRIM-SULFAMETHOXAZOLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4205629\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/489\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/489|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/57/42898\" title=\"table 1\">",
"      Drugs for parasitic infections protozoa",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23221?source=related_link\">",
"      Anthelminthic therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20809?source=related_link\">",
"      Antimalarial drugs: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14356?source=related_link\">",
"      Antitrypanosomal drug therapy for Chagas disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32834?source=related_link\">",
"      Balantidium coli infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38681?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of African trypanosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39321?source=related_link\">",
"      Clinical manifestations, diagnosis, treatment, and prevention of babesiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31493?source=related_link\">",
"      Cyclospora infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35237?source=related_link\">",
"      Dientamoeba fragilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30405?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Cystoisospora infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13961?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33031?source=related_link\">",
"      Extraintestinal Entamoeba histolytica amebiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16742?source=related_link\">",
"      Gastrointestinal Chagas disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33671?source=related_link\">",
"      Intestinal Entamoeba histolytica amebiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31817?source=related_link\">",
"      Metronidazole: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16089?source=related_link\">",
"      Microsporidiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=related_link\">",
"      Primary prevention of opportunistic infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2889?source=related_link\">",
"      Prophylaxis against Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=related_link\">",
"      Toxoplasmosis and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=related_link\">",
"      Toxoplasmosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6424?source=related_link\">",
"      Treatment and prevention of giardiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16184?source=related_link\">",
"      Treatment and prognosis of Chagas heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=related_link\">",
"      Treatment of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43625?source=related_link\">",
"      Treatment of visceral leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1881?source=related_link\">",
"      Trichomonas vaginalis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_59_17336="Progressive multifocal leukoencephalopathy: Prognosis and treatment";
var content_f16_59_17336=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Progressive multifocal leukoencephalopathy: Prognosis and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/59/17336/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/59/17336/contributors\">",
"     Igor J Koralnik, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/59/17336/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/59/17336/contributors\">",
"     Francisco Gonzalez-Scarano, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/59/17336/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/59/17336/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/59/17336/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive multifocal leukoencephalopathy (PML) is a deadly demyelinating disease of the central nervous system (CNS) that occurs almost exclusively in immunosuppressed individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/1\">",
"     1",
"    </a>",
"    ]. This disease is caused by a reactivation of the polyomavirus JC (JCV) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/2\">",
"     2",
"    </a>",
"    ]. Asymptomatic primary JCV infection occurs in childhood and antibodies can be found in 86 percent of adults [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/3\">",
"     3",
"    </a>",
"    ]. In most individuals, JCV remains latent in kidneys and lymphoid organs, but, in the context of profound cellular immunosuppression, it may reactivate, spread to the brain, and induce a lytic infection of oligodendrocytes, the CNS myelin-producing cells.",
"   </p>",
"   <p>",
"    Although there is no proven effective treatment for polyomavirus infection, this topic will review the various approaches that have been employed to treat PML.",
"   </p>",
"   <p>",
"    The epidemiology of JC viral infection and the clinical manifestations and diagnosis of PML are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1734?source=see_link\">",
"     \"Epidemiology of JC and BK virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=see_link\">",
"     \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disease course of PML is usually progressive and fatal. The median survival of patients without HIV infection is only three months.",
"   </p>",
"   <p>",
"    Before highly active antiretroviral therapy (HAART), only 10 percent of patients with HIV infection and PML survived longer than one year [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/4\">",
"     4",
"    </a>",
"    ]. With HAART, the one-year survival rate has increased to 50 percent or more [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. In a nationwide Danish cohort study of all patients &ge;16 years old with HIV infection, the median survival time increased from 0.4 years (95% CI 0.0-0.7) in those diagnosed with PML before 1997 (pre-HAART era) to 1.8 years (95% CI 0.9-2.6) in those diagnosed with PML from 1997 to 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/5\">",
"     5",
"    </a>",
"    ]. While survival in the HAART era is longer, remyelination does not occur in affected areas of the brain, and 55 to 80 percent of PML survivors are left with severe neurologic sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with multiple sclerosis who develop",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    -associated PML, long-term follow-up is not yet available. The available evidence suggests that survival is as high as 70 percent, but most survivors have moderate to severe disability. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Natalizumab-associated PML'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As already noted, there is no specific treatment for JCV. Since PML has a high mortality rate, numerous drugs have been tried empirically in this disease, but none has proven effective. Candidate drugs for PML in patients with HIV infection that failed to demonstrate clear benefit in clinical studies include interferon alpha-2b [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/8\">",
"     8",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/9\">",
"     9",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    How JCV penetrates glial cells is not clearly understood. The 5HT2a serotonin receptor has been identified as a cellular receptor for JCV [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/13\">",
"     13",
"    </a>",
"    ]. Although this finding has not yet translated into the clinic, serotonin receptor antagonists, which down regulate receptors on the cell surface, may play a role in the future prophylaxis or treatment of PML. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Mirtazapine'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Highly active antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with HIV infection who have PML, optimization or initiation of highly active antiretroviral therapy (HAART) is the best therapeutic option [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/14\">",
"     14",
"    </a>",
"    ]. PML may improve or stabilize with potent antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/15-17\">",
"     15-17",
"    </a>",
"    ], leading to prolonged survival [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients treated with HAART therapy have a one-year survival rate of about 50 percent, compared with approximately 10 percent in those not treated with HAART therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of HIV infection with antiretroviral therapy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=see_link\">",
"     \"Modifying HIV antiretroviral therapy regimens\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Stopping immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;PML occurs almost exclusively in immunosuppressed individuals. In the absence of HIV infection, PML is rare but is most likely to be found in patients with lymphoproliferative and myeloproliferative diseases, solid organ malignancies, granulomatous and inflammatory diseases, and in those on antirejection immunosuppressive drugs after organ transplantation, or in those treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In patients without HIV infection who have PML, we suggest discontinuing or decreasing any potential sources of immunosuppression, such as glucocorticoids or calcineurin inhibitors in transplant recipients. The benefit of this intervention is unproven, and is obviously associated with an increased risk of rejection in patients with organ transplants, or relapse in patients with inflammatory diseases. However, possible benefit is suggested by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are case reports of renal transplant recipients who survived PML after immunosuppression was reduced or discontinued [",
"      <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two patients with dermatomyositis who developed PML while on immunosuppressive therapy were noted to improve with regard to the clinical and radiologic manifestations of PML after partial taper or cessation of immunosuppressive treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/20\">",
"       20",
"      </a>",
"      ]. Both patients were also treated with one or more courses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily for five days) when the diagnosis of PML was established, and one of them was treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cytarabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a randomized controlled trial involving 57 patients with HIV infection and biopsy-confirmed PML,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (cytosine arabinoside; ARA-C) administered either intravenously or intrathecally did not improve prognosis compared with antiretroviral therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/9\">",
"     9",
"    </a>",
"    ]. However, there is evidence that cytarabine decreases JCV replication and multiplication in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, an open label study involving 19 patients who had PML without HIV infection found that intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily for five days appeared to stabilize the neurologic and functional status of seven patients (36 percent) at two to four and a half years of follow-up, despite significant bone marrow toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/22\">",
"     22",
"    </a>",
"    ]. The patients in this study had a variety of underlying conditions, including Hodgkin's and non-Hodgkin lymphoma, chronic lymphocytic leukemia, dermatomyositis, sarcoidosis, systemic lupus erythematosus, heart and liver transplantation, and vasculitis. Patients with organ transplants had their immunosuppression regimens altered but not discontinued.",
"   </p>",
"   <p>",
"    As noted earlier, two patients with dermatomyositis developed PML and improved after reduction in immunosuppressive therapy and initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Stopping immunosuppressive therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Therefore, in patients with PML who have ongoing hematologic malignancies - but not HIV infection - we suggest treatment with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily for five days despite clinically significant toxicity and the limited evidence of benefit. We make this suggestion because of the grave prognosis and lack of proven therapy for PML. Only patients with adequate bone marrow reserves can be treated with cytarabine. Preexisting severe pancytopenia (eg, due to chemotherapy for the underlying disease) is a contraindication for cytarabine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cidofovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     Cidofovir",
"    </a>",
"    has been used in patients with HIV infection as treatment for PML, but the largest clinical studies have reported no benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. As an example, a multicenter trial performed in the United States found that cidofovir treatment provided no significant additional benefit over HAART therapy in patients with HIV infection and PML [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/10\">",
"     10",
"    </a>",
"    ]. These disappointing results were confirmed in retrospective studies from Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/6,23,24\">",
"     6,23,24",
"    </a>",
"    ]. In addition, an analysis of pooled data from six studies that included a total of 375 patients with PML and HIV infection found that cidofovir treatment was not associated with improved survival or disability [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/25\">",
"     25",
"    </a>",
"    ]. Similarly, there was no benefit with cidofovir in patients without HIV infection who had PML [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    American guidelines for treating opportunistic infections in adults and adolescents with HIV infection conclude that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    for PML is NOT recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Topotecan",
"    </span>",
"    &nbsp;&mdash;&nbsp;The topoisomerase inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    is a candidate for the treatment of PML based on the knowledge that topoisomerases are required to unwind the double stranded circular viral DNA and thus allow viral replication.",
"   </p>",
"   <p>",
"    In a pilot study, 3 of 11 patients with HIV infection and PML showed a response to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/12\">",
"     12",
"    </a>",
"    ]. Clinical response was defined as an improvement in the Kurtzke disability score (",
"    <a class=\"graphic graphic_table graphicRef76465 \" href=\"UTD.htm?26/34/27179\">",
"     table 1",
"    </a>",
"    ) of 0.5 or more and radiological response was defined as a decrease in PML lesion volume on MRI of &ge;10 percent. However, topotecan was poorly tolerated, and severe anemia, leukopenia, and thrombocytopenia were frequent side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mirtazapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro studies have provided evidence that JC virus may infect cells through the serotonin receptor 5HT2a, suggesting a potential role for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    , a serotonin reuptake inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although data are limited to a few cases,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    may offer some benefit for patients with PML.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In HIV negative patients, a case report described a woman with biopsy-proven PML who had subsequent clinical and radiologic improvement within a month of initiating",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/28\">",
"       28",
"      </a>",
"      ]. In addition, a patient with PML and dermatomyositis may have benefited from mirtazapine, although the patient also received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/20\">",
"       20",
"      </a>",
"      ]. In contrast, a patient with hepatitis C had a rapid fatal outcome from PML despite mirtazapine and cytarabine [",
"      <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with HIV infection, a case series reported that treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      15 mg daily was associated with objective clinical improvement in three of four patients [",
"      <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/30\">",
"       30",
"      </a>",
"      ]. While improvement seemed to follow initiation of mirtazapine, HAART was also used or initiated for PML treatment, so it is uncertain whether mirtazapine was effective. A controlled trial would be needed to settle the issue.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    for patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    -associated PML is discussed below. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Natalizumab-associated PML'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mefloquine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antimalarial drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    has some anti-JCV activity in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/31\">",
"     31",
"    </a>",
"    ]. However, a randomized trial evaluating mefloquine for the treatment of PML was stopped prematurely because an interim analysis found that mefloquine failed to reduce JC viral DNA levels in the cerebrospinal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Therefore, we no longer suggest using this drug to treat patients with PML.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Inflammatory PML",
"    </span>",
"    &nbsp;&mdash;&nbsp;While glucocorticoids have been used in inflammatory forms of PML, retrospective data from case studies and small series suggest that patients with inflammatory PML generally have a favorable outcome despite transient worsening of neurologic symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=see_link&amp;anchor=H7#H7\">",
"     \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\", section on 'Inflammatory PML'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Short-term glucocorticoid therapy may be beneficial for patients who have inflammatory PML when there is neurologic deterioration associated with evidence of brain swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. However, there are no formal controlled trials that address this issue. The best available evidence comes from a retrospective review that reported 54 patients with PML and immune reconstitution inflammatory syndrome (IRIS) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/35\">",
"     35",
"    </a>",
"    ]. Twelve patients were treated with glucocorticoids, most often for catastrophic deterioration or for evidence of brain inflammation on neuroimaging.",
"   </p>",
"   <p>",
"    The following outcomes were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall mortality was 35 percent",
"     </li>",
"     <li>",
"      Comparing patients treated (n = 12) and those not treated (n = 42) with glucocorticoids, there were no statistically significant differences on any baseline or outcome measure, including duration of survival or mortality",
"     </li>",
"     <li>",
"      Among 12 patients treated with glucocorticoids, seven survived with good neurologic recovery, and five died. Comparing these two groups, several trends were observed:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Survivors received glucocorticoids earlier after the recognition of IRIS (mean 3 versus 12.3 weeks), received longer courses of glucocorticoids (mean 13.3 versus 3 weeks), and were tapered off glucocorticoids more slowly. However, these differences were NOT statistically significant.",
"     </li>",
"     <li>",
"      Survivors were nonsignificantly more likely to have contrast enhancement of PML-IRIS on brain MRI scan (six of seven versus one of five).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the available data are limited, we suggest high-dose glucocorticoid therapy for patients with HIV infection who develop inflammatory PML associated with both neurologic deterioration and clinical or radiologic evidence of brain swelling, since these can lead to mass effect, brain herniation, and death. Reasonable regimens include either intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (32 mg daily given in four divided doses) for two weeks, or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (1 g daily for five days), both followed by a slow glucocorticoid taper. High-dose glucocorticoids can be given without temporary interruption of HAART therapy.",
"   </p>",
"   <p>",
"    Since glucocorticoids are immunosuppressants, we suggest NOT treating patients who have inflammatory PML with glucocorticoids unless there is major neurologic worsening associated with clinical or radiologic evidence of brain swelling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Natalizumab-associated PML",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     Natalizumab",
"    </a>",
"    should be discontinued in patients with multiple sclerosis who develop PML. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23032?source=see_link&amp;anchor=H4#H4\">",
"     \"Natalizumab for relapsing-remitting multiple sclerosis in adults\", section on 'Risk of progressive multifocal leukoencephalopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Empiric treatment with plasma exchange or immunoadsorption or both has been tried in over 35 patients with multiple sclerosis who developed PML while being treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/36-40\">",
"     36-40",
"    </a>",
"    ]. The rationale is to eliminate circulating natalizumab, which has a long duration of action that might delay immune reconstitution. In one report of 35 patients of natalizumab-associated PML, 32 patients (91 percent) developed an immune reconstitution inflammatory syndrome (IRIS), usually within weeks after stopping natalizumab and starting treatment with plasma exchange or immunoadsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. IRIS usually presented with subacute onset of new symptoms or with worsening of symptoms attributed to PML. The mean time from initiation of plasma exchange or immunoadsorption to the onset of IRIS was just over 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/39\">",
"     39",
"    </a>",
"    ]. Most of the reported patients who developed IRIS in this setting had severe cases and were treated with high-dose glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. IRIS also developed several months after stopping natalizumab in a patient who was not treated with plasma exchange or immunoadsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In retrospective data, clinical features associated with survival in the first 35 cases of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    -associated PML were younger age at diagnosis, less disability prior to PML onset, localized brain lesions on MRI, and a shorter time from symptom onset to PML diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following case reports illustrate the clinical course in three survivors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One patient briefly improved within a week after treatment consisting of plasma exchange, immunoadsorption,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       mefloquine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/36\">",
"       36",
"      </a>",
"      ]. He then became critically ill with the development of IRIS, which was treated with two cycles of glucocorticoid pulse therapy. Neurologic improvement followed within four weeks.",
"     </li>",
"     <li>",
"      Another patient continued to deteriorate and developed IRIS at about three weeks after starting plasma exchange and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/37\">",
"       37",
"      </a>",
"      ]. At five weeks, he was given intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      for three days to treat new cerebellar lesions attributed to a relapse of multiple sclerosis. The clinical course stabilized six to eight weeks after plasma exchange. Brain MRI showed changes consistent with laminar necrosis, presumably secondary to IRIS.",
"      <br/>",
"      <br/>",
"      Both patients partially recovered over months, with residual disabling hemiparesis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third patient who developed PML was treated with five courses plasma exchange and started on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       mefloquine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/41\">",
"       41",
"      </a>",
"      ]. One week later, the patient developed IRIS that was treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      for five days and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      for four days. After three months of treatment, the patient had clinically improved to the baseline disability level that was present before the onset of PML, and cerebrospinal fluid analysis by polymerase chain reaction detected no JC virus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In an earlier case report, one patient with multiple sclerosis and PML associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    treatment had significant clinical improvement two weeks after starting treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/42\">",
"     42",
"    </a>",
"    ]. This improvement was concomitant with a massive inflammatory reaction (IRIS) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/43\">",
"     43",
"    </a>",
"    ]. The breakdown of the blood-brain-barrier in this patient may have promoted the intraparenchymal distribution of cytarabine, which otherwise has a poor central nervous system penetration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=see_link&amp;anchor=H7#H7\">",
"     \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\", section on 'Inflammatory PML'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the limited observational data do not permit any conclusions about optimal treatment, we suggest a course of plasma exchange (eg, every other day for a total of five treatments) accompanied by oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    (15 mg at bed time) for patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    -associated PML. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=see_link\">",
"     \"Prescription and technique of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians should be aware that IRIS is likely to develop approximately three to six weeks after plasma exchange or immunoadsorption. In addition, IRIS may develop in patients with PML weeks to months after discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    even when plasma exchange or immunoadsorption are not employed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17336/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. We suggest high-dose glucocorticoid therapy for patients who develop IRIS and have both neurologic deterioration and evidence (clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiologic) of brain swelling. Reasonable regimens include either intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (32 mg daily given in four divided doses) for two weeks, or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (1 g daily for five days), both followed by a slow glucocorticoid taper.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progressive multifocal leukoencephalopathy (PML) is usually fatal, and the median survival of patients without HIV infection is only 2.6 months. In patients with HIV infection and PML, the median survival for patients has increased from 0.4 years in the era before highly active antiretroviral therapy (HAART) to 1.8 years with widespread use of HAART. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Natural history and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no specific treatment for polyomavirus infection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with PML and HIV infection, we recommend initiation and optimization of HAART therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Highly active antiretroviral therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"       \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=see_link\">",
"       \"Modifying HIV antiretroviral therapy regimens\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with HIV infection who develop both neurologic deterioration and clinical or radiologic evidence of brain swelling associated with inflammatory PML, we suggest high-dose glucocorticoid therapy without interruption of HAART therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Reasonable regimens include either intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (32 mg daily given in four divided doses) for two weeks, or intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (1 g daily for five days), both followed by a slow glucocorticoid taper. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Inflammatory PML'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who have PML without HIV infection, we recommend stopping or decreasing immunosuppression therapy (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ) since PML is usually a progressive fatal disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Stopping immunosuppressive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with PML who have ongoing hematologic malignancies &mdash; but not HIV infection &mdash; we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily for five days (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ), given evidence from observational studies of some benefit in patients without HIV infection, but no benefit in a randomized controlled trial involving patients with HIV infection. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Cytarabine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with multiple sclerosis who develop PML during",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      treatment, natalizumab should be immediately discontinued. In addition, we suggest a course of plasma exchange accompanied by treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In these patients, an immune reconstitution inflammatory syndrome (IRIS) is likely to develop approximately three to six weeks after plasma exchange. For patients who develop IRIS and have both neurologic deterioration and evidence of brain swelling, we suggest high-dose glucocorticoid therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Reasonable regimens include either intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (32 mg daily given in four divided doses) for two weeks, or intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (1 g daily for five days), both followed by a slow glucocorticoid taper. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Natalizumab-associated PML'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Inflammatory PML'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/1\">",
"      ASTROM KE, MANCALL EL, RICHARDSON EP Jr. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 1958; 81:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/2\">",
"      Padgett BL, Walker DL, ZuRhein GM, et al. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971; 1:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/3\">",
"      Weber T, Trebst C, Frye S, et al. Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J Infect Dis 1997; 176:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/4\">",
"      Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 1998; 4:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/5\">",
"      Engsig FN, Hansen AB, Omland LH, et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis 2009; 199:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/6\">",
"      Antinori A, Cingolani A, Lorenzini P, et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003; 9 Suppl 1:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/7\">",
"      Marzocchetti A, Tompkins T, Clifford DB, et al. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 2009; 73:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/8\">",
"      Geschwind MD, Skolasky RI, Royal WS, McArthur JC. The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J Neurovirol 2001; 7:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/9\">",
"      Hall CD, Dafni U, Simpson D, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 1998; 338:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/10\">",
"      Marra CM, Rajicic N, Barker DE, et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS 2002; 16:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/11\">",
"      Wyen C, Hoffmann C, Schmeisser N, et al. Progressive multifocal leukencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death. J Acquir Immune Defic Syndr 2004; 37:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/12\">",
"      Royal W 3rd, Dupont B, McGuire D, et al. Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy. J Neurovirol 2003; 9:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/13\">",
"      Elphick GF, Querbes W, Jordan JA, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 2004; 306:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/14\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/15\">",
"      Elliot B, Aromin I, Gold R, et al. 2.5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy. Lancet 1997; 349:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/16\">",
"      Albrecht H, Hoffmann C, Degen O, et al. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS 1998; 12:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/17\">",
"      Cinque P, Casari S, Bertelli D. Progressive multifocal leukoencephalopathy, HIV, and highly active antiretroviral therapy. N Engl J Med 1998; 339:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/18\">",
"      Antinori A, Ammassari A, Giancola ML, et al. Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. J Neurovirol 2001; 7:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/19\">",
"      Crowder CD, Gyure KA, Drachenberg CB, et al. Successful outcome of progressive multifocal leukoencephalopathy in a renal transplant patient. Am J Transplant 2005; 5:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/20\">",
"      Vulliemoz S, Lurati-Ruiz F, Borruat FX, et al. Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis. J Neurol Neurosurg Psychiatry 2006; 77:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/21\">",
"      Hou J, Major EO. The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line. J Neurovirol 1998; 4:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/22\">",
"      Aksamit AJ. Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside. J Neurovirol 2001; 7:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/23\">",
"      Gasnault J, Kousignian P, Kahraman M, et al. Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: a monocenter observational study with clinical and JC virus load monitoring. J Neurovirol 2001; 7:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/24\">",
"      Berenguer J, Miralles P, Arrizabalaga J, et al. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2003; 36:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/25\">",
"      De Luca A, Ammassari A, Pezzotti P, et al. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS 2008; 22:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/26\">",
"      Osorio S, de la C&aacute;mara R, Golbano N, et al. Progressive multifocal leukoencephalopathy after stem cell transplantation, unsuccessfully treated with cidofovir. Bone Marrow Transplant 2002; 30:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/27\">",
"      Herrlinger U, Schw&auml;rzler F, Beck R, et al. Progressive multifocal leukoencephalopathy: cidofovir therapy in three patients with underlying hematological disease. J Neurol 2003; 250:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/28\">",
"      Verma S, Cikurel K, Koralnik IJ, et al. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis 2007; 196:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/29\">",
"      Lima MA, Auriel E, W&uuml;thrich C, et al. Progressive multifocal leukoencephalopathy as a complication of hepatitis C virus treatment in an HIV-negative patient. Clin Infect Dis 2005; 41:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/30\">",
"      Cettomai D, McArthur JC. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol 2009; 66:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/31\">",
"      Brickelmaier M, Lugovskoy A, Kartikeyan R, et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 2009; 53:1840.",
"     </a>",
"    </li>",
"    <li>",
"     Study to explore the effect of mefloquine in subjects with progressive multifocal leukoencephalopathy (PML). file://clinicaltrials.gov/ct2/show/NCT00746941 (Accessed on April 14, 2011).",
"    </li>",
"    <li>",
"     News from the AAN Annual Meeting: Malaria drug fails to fulfill promise in PML. www.aan.com/elibrary/neurologytoday/?event=home.showArticle&amp;id=ovid.com:/bib/ovftdb/00132985-201104210-00004 (Accessed on June 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/34\">",
"      Martinez JV, Mazziotti JV, Efron ED, et al. Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder. Neurology 2006; 67:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/35\">",
"      Tan K, Roda R, Ostrow L, et al. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009; 72:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/36\">",
"      Wenning W, Haghikia A, Laubenberger J, et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 2009; 361:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/37\">",
"      Lind&aring; H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009; 361:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/38\">",
"      Clifford DB, De Luca A, DeLuca A, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/39\">",
"      Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 2011; 76:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/40\">",
"      Tan IL, McArthur JC, Clifford DB, et al. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 2011; 77:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/41\">",
"      Schr&ouml;der A, Lee DH, Hellwig K, et al. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Arch Neurol 2010; 67:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/42\">",
"      Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/43\">",
"      Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences. N Engl J Med 2005; 353:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/44\">",
"      Groothuis DR, Benalcazar H, Allen CV, et al. Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration. Brain Res 2000; 856:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/45\">",
"      Vennegoor A, Wattjes MP, van Munster ET, et al. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology 2011; 76:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17336/abstract/46\">",
"      Clifford DB. Lessons from the clinic: a case of natalizumab-associated PML. Neurology 2011; 76:574.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1697 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-B28792CD2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_59_17336=[""].join("\n");
var outline_f16_59_17336=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NATURAL HISTORY AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Highly active antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Stopping immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cytarabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cidofovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Topotecan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mirtazapine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mefloquine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Inflammatory PML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Natalizumab-associated PML",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1697\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1697|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/34/27179\" title=\"table 1\">",
"      Kurtzke disability status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1734?source=related_link\">",
"      Epidemiology of JC and BK virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=related_link\">",
"      Modifying HIV antiretroviral therapy regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23032?source=related_link\">",
"      Natalizumab for relapsing-remitting multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=related_link\">",
"      Prescription and technique of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_59_17337="Overview of the complications, prognosis, and management of cirrhosis";
var content_f16_59_17337=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the complications, prognosis, and management of cirrhosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/59/17337/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/59/17337/contributors\">",
"     Eric Goldberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/59/17337/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/59/17337/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/59/17337/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/59/17337/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/59/17337/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/59/17337/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cirrhosis represents a late stage of progressive hepatic fibrosis characterized by distortion of the hepatic architecture and the formation of regenerative nodules. It is generally considered to be irreversible in its advanced stages at which point the only option may be liver transplantation. In earlier stages, specific treatments aimed at the underlying cause of liver disease can improve or even reverse cirrhosis. Furthermore, there has been exciting progress in understanding hepatic fibrosis, which represents a paradigm for wound healing in other tissues, including skin, lung, and kidney, since it involves many of the same cell types and mediators. An understanding of these mechanisms has a number of clinical implications, including the development of interventions designed to impede or reverse hepatic fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13242?source=see_link\">",
"     \"Emerging therapies for hepatic fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with cirrhosis are susceptible to a variety of complications and their life expectancy can be markedly reduced. Cirrhosis and chronic liver disease accounted for more than 25,000 deaths and 373,000 hospital discharges in the United States in 1998 according to a report from The National Center for Health Statistics [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/1\">",
"     1",
"    </a>",
"    ]. Multiple factors can predispose to decompensation in a patient with cirrhosis. Risk factors for decompensation include bleeding, infection, alcohol intake, medications, dehydration, and constipation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In addition, patients with obesity are at increased risk for decompensation. In one study, clinical decompensation occurred significantly more often in obese patients compared with patients who were overweight or who had a normal body mass index (43 versus 31 and 15 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the complications, prognosis, and general management issues in patients with cirrhosis. An overview of the causes and diagnosis of cirrhosis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=see_link\">",
"     \"Diagnostic approach to the patient with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a patient develops complications of cirrhosis, they are considered to have decompensated disease (",
"    <a class=\"graphic graphic_table graphicRef65667 \" href=\"UTD.htm?0/56/907\">",
"     table 1",
"    </a>",
"    ). The high morbidity and mortality of cirrhosis is secondary to these devastating complications. The quality of life and survival of patients with cirrhosis can be improved by the prevention and treatment of these complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ascites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ascites is the accumulation of fluid within the peritoneal cavity. It is the most common complication of cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14010?source=see_link\">",
"     \"Evaluation of adults with ascites\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The first step leading to fluid retention and ultimately ascites in patients with cirrhosis is the development of portal hypertension. Patients without portal hypertension do not develop ascites or edema. Those with ascites have several circulatory, vascular, functional, and biochemical abnormalities that contribute to the pathogenesis of fluid retention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21527?source=see_link\">",
"     \"Pathogenesis of ascites in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Spontaneous bacterial peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous bacterial peritonitis (SBP) is an infection of preexisting ascitic fluid without evidence for an intra-abdominal secondary source such as a perforated viscus. SBP is almost always seen in the setting of end-stage liver disease. Clinical manifestations of SBP include fever, abdominal pain, abdominal tenderness, and altered mental status. Some patients are asymptomatic and present with only mild laboratory abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/0/7172?source=see_link\">",
"     \"Clinical manifestations of spontaneous bacterial peritonitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34197?source=see_link\">",
"     \"Pathogenesis of spontaneous bacterial peritonitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The index of suspicion for SBP must be high with a low threshold for diagnostic paracentesis. The diagnosis is established by a positive ascitic fluid bacterial culture",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an elevated ascitic fluid absolute polymorphonuclear leukocyte (PMN) count (&ge;250",
"    <span class=\"nowrap\">",
"     cells/mm3).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12296?source=see_link\">",
"     \"Diagnosis of spontaneous bacterial peritonitis\"",
"    </a>",
"    .) Without early treatment, mortality is high. Efforts to prevent SBP should be made in high-risk patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4121?source=see_link\">",
"     \"Treatment and prophylaxis of spontaneous bacterial peritonitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233194597\">",
"    <span class=\"h2\">",
"     Hospital-acquired secondary infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cirrhosis who are hospitalized often acquire infections while in the hospital. In a study of 207 patients with cirrhosis who were admitted with or developed an infection during hospitalization, 50 (24 percent) developed a second infection during hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/6\">",
"     6",
"    </a>",
"    ]. Respiratory infections were the most common (14 patients), followed by urinary tract infections (13 patients), and Clostridium difficile. Of the urinary tract infections, 6 (46 percent) were related to the use of bladder catheters. Other factors associated with second infections included intensive care unit admission, the use of central lines, mechanical ventilation, shock, renal replacement therapy, and hepatic encephalopathy. Overall mortality was 39 percent, but it was 48 percent for those who developed a second infection during admission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hepatorenal syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hepatorenal syndrome refers to the development of renal failure in a patient who has advanced liver disease due to cirrhosis, severe alcoholic hepatitis, fulminant hepatic failure, or, less often, a metastatic tumor. Rather than being a new disease, the hepatorenal syndrome usually represents the end-stage of a sequence of reductions in renal perfusion induced by increasingly severe hepatic injury. The initial reductions in glomerular filtration rate are often masked clinically since associated decreases in muscle mass and hepatic urea production minimize elevations in the plasma creatinine concentration and blood urea nitrogen.",
"   </p>",
"   <p>",
"    The hepatorenal syndrome is characterized by generally benign urine sediment, a very low rate of sodium excretion, and a progressive rise in the plasma creatinine concentration. There is some confusion regarding the presence or absence of oliguria. The percentage of patients with oliguria depends upon the cut-off for defining oliguria. If the cut-off is 400",
"    <span class=\"nowrap\">",
"     mL/day,",
"    </span>",
"    only 44 percent are oliguric. If 500",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    is used, about two-thirds are oliguric. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=see_link\">",
"     \"Hepatorenal syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis is one of exclusion, being made when other causes of renal dysfunction have been excluded. In particular, volume depletion (as with overly-rapid diuresis) can mimic all of the findings of hepatorenal syndrome. The prognosis is poor unless hepatic function improves or a liver transplant is performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=see_link\">",
"     \"Hepatorenal syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Variceal hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variceal hemorrhage is a devastating complication of cirrhosis. Before the widespread use of current therapies for acute variceal hemorrhage, the mortality rate of a single variceal hemorrhage was 30 percent, and only one-third of patients survived for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Although survival has improved with modern techniques for controlling variceal hemorrhage, mortality rates remain high. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21446?source=see_link\">",
"     \"Prediction of variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hepatopulmonary syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hepatopulmonary syndrome (HPS) is considered to be present in patients with the following triad:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Liver disease",
"     </li>",
"     <li>",
"      Increased alveolar-arterial gradient while breathing room air",
"     </li>",
"     <li>",
"      Evidence for intrapulmonary vascular abnormalities, referred to as intrapulmonary vascular dilatations (IPVDs)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Estimates of the prevalence of HPS among patients with chronic liver disease range from 4 to 47 percent, depending upon the diagnostic criteria and methods used. Even in those without HPS, mild hypoxemia is common and is presumably caused by ascites, with resulting diaphragmatic elevation and",
"    <span class=\"nowrap\">",
"     ventilation/perfusion",
"    </span>",
"    mismatch. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/35/3640?source=see_link\">",
"     \"Hepatopulmonary syndrome: Prevalence, causes, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other pulmonary syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic hydrothorax and portopulmonary hypertension are two other pulmonary complications that may develop in patients with cirrhosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatic hydrothorax is defined as the presence of a pleural effusion in a patient with cirrhosis and no evidence of underlying cardiopulmonary disease. It results from the movement of ascitic fluid into the pleural space through defects in the diaphragm, and it is usually right-sided. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30263?source=see_link\">",
"       \"Hepatic hydrothorax\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Portal hypertension associated pulmonary hypertension (portopulmonary hypertension) refers to the presence of pulmonary hypertension in patients with portal hypertension. The prevalence in patients with cirrhosis is approximately 2 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/9\">",
"       9",
"      </a>",
"      ]. Neither the prevalence nor the severity of portopulmonary hypertension appears to correlate with the degree of portal hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with portopulmonary hypertension may present with fatigue, dyspnea, peripheral edema, chest pain, and syncope. Diagnosis may be suggested by echocardiography and confirmed by right heart catheterization. Patients with moderate to severe portopulmonary hypertension are difficult to treat with medical therapy and the perioperative mortality with liver transplantation is high. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35064?source=see_link\">",
"     \"Portopulmonary hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H124251188\">",
"    <span class=\"h2\">",
"     Cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up To 50 percent of patients with advanced cirrhosis have features of cardiac dysfunction. The term \"cirrhotic cardiomyopathy\" has been used to describe such patients, who are characterized as having normal to increased cardiac output and contractility at rest, but a blunted response to pharmacologic, physiologic or pathologic stress [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/10\">",
"     10",
"    </a>",
"    ]. Cardiomyopathy can occur from any cause of cirrhosis, although patients who are alcoholic or have hemochromatosis may have additional contributing causes to cardiac dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9978?source=see_link&amp;anchor=H18#H18\">",
"     \"High-output heart failure\", section on 'Cirrhosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hepatic encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic encephalopathy describes the spectrum of potentially reversible neuropsychiatric abnormalities seen in patients with liver dysfunction. Disturbance in the diurnal sleep pattern (insomnia and hypersomnia) is a common early feature that typically precedes overt neurologic signs (",
"    <a class=\"graphic graphic_figure graphicRef58163 \" href=\"UTD.htm?37/16/38158\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70740 \" href=\"UTD.htm?12/37/12883\">",
"     figure 2",
"    </a>",
"    ). More advanced neurologic features include the presence of asterixis, hyperactive deep tendon reflexes, and, less commonly, transient decerebrate posturing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34153?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hepatic encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hepatocellular carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cirrhosis have a markedly increased risk of developing hepatocellular carcinoma (HCC). Patients with most forms of chronic hepatitis are not at an increased risk until cirrhosis develops. Exceptions to this rule are patients with chronic hepatitis B virus infection who can develop HCC in the absence of cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=see_link\">",
"     \"Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain causes of cirrhosis appear to have a relatively increased risk for HCC. Patients with cirrhosis from hepatitis B, hepatitis C, nonalcoholic steatohepatitis, and hemochromatosis are at the highest risk, while those with cirrhosis from autoimmune hepatitis and Wilson's disease appear to have a lower risk.",
"   </p>",
"   <p>",
"    Because of the large functional reserve of the liver, patients with HCC are often asymptomatic early in its course. Thus, the diagnosis is often delayed. Decompensation in a patient with previously compensated cirrhosis should raise the clinical suspicion that HCC has developed. Other common signs and symptoms of hepatocellular carcinoma are usually related to mass effect from the tumor and include pain, early satiety, obstructive jaundice, and a palpable mass. Hepatocellular carcinomas can rupture, causing hemoperitoneum. Paraneoplastic manifestations include erythrocytosis, hypercalcemia, hypoglycemia, and diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link\">",
"     \"Clinical features and diagnosis of primary hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of HCC can be suggested by marked elevations of serum alpha-fetoprotein (AFP) or by characteristic radiographic findings. Elevated AFP is not specific for HCC since it can also be seen in patients with acute or chronic hepatitis, gonadal tumors, and pregnancy. However, rising serum AFP levels in patients with cirrhosis should raise clinical suspicion for HCC. A significant proportion of patients with HCC have normal AFP levels, especially when the tumor is small. As a result, a normal AFP does not preclude a diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link\">",
"     \"Clinical features and diagnosis of primary hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Portal vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Portal vein thrombosis can develop in patients with cirrhosis and contribute to the development of portal hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link&amp;anchor=H5858393#H5858393\">",
"     \"Coagulation abnormalities in patients with liver disease\", section on 'Portal vein thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Muscle cramps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cirrhosis may experience muscle cramps, which can be severe [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. The cause is incompletely understood, although they may be related to a reduction in effective circulating plasma volume. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4711?source=see_link\">",
"     \"Nocturnal leg cramps\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We have treated patients successfully with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    sulfate, but it is no longer available for treatment of cramps. Note that quinine sulfate is NOT the same as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    sulfate (the latter being an antiarrhythmic drug). While there are no data, we have found that the small amount of quinine contained in tonic water has been clinically helpful. We ask patients to try drinking 3 to 4 ounces, assessing the clinical response and repeating as needed.",
"   </p>",
"   <p>",
"    Patients with leg cramps often have advanced liver disease; we generally follow such patients with electrolytes, a complete blood count, and INR with each clinic visit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of cirrhosis is highly variable since it is influenced by a number of factors, including etiology, severity, presence of complications, and comorbid diseases. Multiple studies have attempted to predict the prognosis of patients with cirrhosis based upon clinical and laboratory information. One of the earliest models (the Child's classification) continues to be a useful method for stratifying disease severity, surgical risk, and overall prognosis.",
"   </p>",
"   <p>",
"    Another model to predict prognosis in patients with cirrhosis is the Model for End Stage Liver Disease (MELD). It is based upon bilirubin levels, creatinine, INR, and the etiology of cirrhosis (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?18/2/18466?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). The MELD score has been adopted for use in prioritizing patients awaiting liver transplantation and has an expanding role in predicting outcomes in patients with liver disease in the non-transplant setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=see_link\">",
"     \"Model for End-stage Liver Disease (MELD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Predictive models",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Child-Turcotte classification incorporates five variables that were initially designed to stratify the risk of portacaval shunt surgery in patients with cirrhosis. The variables included the serum albumin and bilirubin, ascites, encephalopathy, and nutritional status (",
"    <a class=\"graphic graphic_table graphicRef56436 \" href=\"UTD.htm?13/0/13323\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/15\">",
"     15",
"    </a>",
"    ]. Modified versions of these criteria, such as the Child-Pugh classification (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"UTD.htm?8/21/8540\">",
"     table 3",
"    </a>",
"    ), have been used to assess the risk of non-shunt operations (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?27/26/28065?source=see_link\">",
"     calculator 3",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?28/28/29121?source=see_link\">",
"     calculator 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/16\">",
"     16",
"    </a>",
"    ]. In one review of 92 patients with cirrhosis who underwent abdominal surgery, the mortality rate was 10 percent for patients with Child-Pugh class A cirrhosis, 30 percent for patients with Child-Pugh class B cirrhosis, and 82 percent for patients with Child-Pugh class C cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/17\">",
"     17",
"    </a>",
"    ]. Other studies have validated the utility of the Child-Pugh classification for the assessment of surgical risk [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12858?source=see_link\">",
"     \"Assessing surgical risk in patients with liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Child-Pugh classification system also correlates with survival in patients not undergoing surgery; one-year survival rates for patients with Child's A, B, and C cirrhosis are approximately 100, 80, and 45 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Child-Pugh class can also predict the development of complications of cirrhosis. As an example, patients with Child-Pugh class C cirrhosis are much more likely to develop variceal hemorrhage than those with Child-Pugh class A cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H145979036\">",
"    <span class=\"h2\">",
"     Decompensated cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decompensated cirrhosis is associated with poor survival. A systematic review found that the median survival is &le;6 months in patients with decompensated cirrhosis and a Child-Pugh score &ge;12 (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?27/26/28065?source=see_link\">",
"     calculator 3",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?28/28/29121?source=see_link\">",
"     calculator 4",
"    </a>",
"    ) or a MELD score &ge;21 (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?18/2/18466?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, patients with decompensated cirrhosis who have been hospitalized with an acute liver-related illnesses (eg, variceal hemorrhage or spontaneous bacterial peritonitis) have a median survival of &le;6 months if the Child-Pugh score is &ge;12 or the MELD score is &ge;18. Other factors associated with poor survival in patients with decompensated cirrhosis include hepatopulmonary syndrome, rapidly progressive hepatorenal syndrome, and intensive care unit admission related to complications of liver disease associated with hypotension requiring pressor support, serum creatinine &gt;1.5",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    or jaundice.",
"   </p>",
"   <p>",
"    Patients with decompensated cirrhosis often require liver transplantation. For those who are not candidates, hospice care can be considered for patients with predicted survival rates of &le;6 months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=see_link\">",
"     \"Patient selection for liver transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29801?source=see_link\">",
"     \"Palliative care: Benefits, services, and models of care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major goals of treating patients with cirrhosis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Slowing or reversing the progression of liver disease",
"     </li>",
"     <li>",
"      Preventing superimposed insults to the liver",
"     </li>",
"     <li>",
"      Preventing and treating the complications",
"     </li>",
"     <li>",
"      Determining the appropriateness and optimal timing for liver transplantation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Slowing or reversing the progression of liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cirrhosis is generally considered to be irreversible in its advanced stages, the exact point at which it becomes irreversible is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/23\">",
"     23",
"    </a>",
"    ]. Some chronic liver diseases respond to treatment even when the liver disease has progressed to cirrhosis. Thus, specific therapies directed against the underlying cause of the cirrhosis should be instituted. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 10-year survival rate in patients with cirrhosis from autoimmune hepatitis who are treated with steroids or immunosuppressive is similar to survival rates of treated patients with autoimmune hepatitis who do not have cirrhosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40058?source=see_link\">",
"       \"Treatment of autoimmune hepatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abstinence from alcohol substantially improves survival in alcoholic cirrhosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22104?source=see_link\">",
"       \"Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Successful treatment of chronic viral hepatitis can improve long-term outcomes and may affect fibrosis. In one study of 91 patients with chronic hepatitis C and significant fibrosis based upon liver elastography, patients who achieved a sustained virologic response had a significant decrease in liver stiffness 24 weeks after the end of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Preventing superimposed insults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cirrhosis should avoid any agent that has the potential to cause additional liver injury. This includes abused substances such as alcohol, over-the-counter medications (such as high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ), prescribed drugs with hepatotoxic side effects, and certain herbal remedies. Although the exact amount of acetaminophen that is safe in cirrhosis is uncertain, we recommend that patients not use more than a total of 2 g per day (in divided doses).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccination against hepatitis A and B can help prevent a superimposed insult to a liver that may have little functional reserve. Pneumococcal vaccine and yearly influenza vaccination should also be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8569?source=see_link\">",
"     \"Immunizations for patients with chronic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Preventing complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the most common complications related to cirrhosis include the development of hepatocellular carcinoma, variceal bleeding, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatic encephalopathy and hepatopulmonary syndrome. Patients should be monitored for the development of these complications, and specific efforts can be made to help prevent some of them.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Hepatocellular carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of surveillance for hepatocellular carcinoma is controversial since a reduction in mortality from surveillance programs has not been consistently demonstrated. Despite the uncertainty, many hepatologists screen patients with serum AFP determinations and ultrasonography every six months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link&amp;anchor=H28#H28\">",
"     \"Clinical features and diagnosis of primary hepatocellular carcinoma\", section on 'Screening and surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Variceal bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cirrhosis should undergo evaluation to document the presence of varices and to determine the risk of variceal hemorrhage. Patients with varices should be treated with prophylactic measures. This most commonly involves treatment with a nonselective beta blocker, which reduces the risk of variceal bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=see_link\">",
"     \"Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Spontaneous bacterial peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of spontaneous bacterial peritonitis can be reduced by efforts to judiciously diurese patients since diuresis concentrates ascitic fluid, thereby raising ascitic fluid opsonic activity. Early recognition and aggressive treatment of localized infections (eg, cystitis, cellulitis) can also help to prevent bacteremia and SBP. Prophylactic antibiotics aimed at decontaminating the gut also have a role in specific clinical settings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4121?source=see_link\">",
"     \"Treatment and prophylaxis of spontaneous bacterial peritonitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233194589\">",
"    <span class=\"h3\">",
"     Secondary infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that have been associated with hospital-acquired secondary infections in patients with cirrhosis include the use of urinary catheters, mechanical ventilation, and the placement of central lines [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/6\">",
"     6",
"    </a>",
"    ]. Many of these interventions are performed routinely (such as placement of urinary catheters to measure urine output). However, avoiding these interventions unless they are absolutely necessary may decrease the risk of acquiring an infection while in the hospital, and it is our practice to only use these interventions when clearly indicated. (See",
"    <a class=\"local\" href=\"#H233194597\">",
"     'Hospital-acquired secondary infections'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Hepatorenal syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrotoxic agents (such as aminoglycosides) and vigorous diuresis should be avoided in patients with cirrhosis since they can precipitate renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=see_link\">",
"     \"Hepatorenal syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Hepatic encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cirrhosis should be evaluated regularly for hepatic encephalopathy, the earliest features of which can be subtle. Events that can precipitate hepatic encephalopathy include the development of variceal bleeding, infection (such as SBP), the administration of sedatives, hypokalemia, and hyponatremia, all of which should be",
"    <span class=\"nowrap\">",
"     corrected/avoided",
"    </span>",
"    whenever possible (",
"    <a class=\"graphic graphic_table graphicRef50440 \" href=\"UTD.htm?0/34/556\">",
"     table 4",
"    </a>",
"    ). A number of measures may be helpful in patients in whom it has developed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34153?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hepatic encephalopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4346?source=see_link\">",
"     \"Hepatic encephalopathy in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H78564944\">",
"    <span class=\"h3\">",
"     Portal vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     Enoxaparin",
"    </a>",
"    may be effective for preventing portal vein thrombosis (PVT) in patients with cirrhosis. A randomized trial with 70 patients with Child-Pugh class B7-C10 cirrhosis found that patients treated for 48 months with enoxaparin were less likely than those who received placebo to develop PVT by 48 weeks (0 versus 17 percent), by 96 weeks (0 versus 28 percent), and by the end of follow-up (9 versus 28 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, during treatment with enoxaparin, hepatic decompensation was less common (12 versus 59 percent), though no difference was seen once treatment was discontinued. Finally, actuarial survival rates were higher among those treated with enoxaparin. One patient in the enoxaparin group had to discontinue treatment for marked thrombocytopenia. Variceal hemorrhage occurred in two patients in the enoxaparin group and in one patient in the placebo group (p = 0.52). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link&amp;anchor=H5858393#H5858393\">",
"     \"Coagulation abnormalities in patients with liver disease\", section on 'Portal vein thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A small study examining the use of low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in patients with cirrhosis and PVT suggests that bleeding complications are rare (0 of 28 patients treated for at least six months) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/26\">",
"     26",
"    </a>",
"    ]. However, in patients with esophageal varices, we suggest variceal eradication prior to initiation of anticoagulation when possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=see_link&amp;anchor=H750670#H750670\">",
"     \"Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis\", section on 'Endoscopic variceal ligation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver transplantation is the definitive treatment for patients with decompensated cirrhosis. It is important to determine whether patients may be eligible for transplantation and to refer them to a transplant center for evaluation. Several guidelines are available which help determine when referral for liver transplantation may be beneficial. The decision to proceed to liver transplantation (either cadaveric or live donor) depends upon the severity of disease, quality of life, and the absence of contraindications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=see_link\">",
"     \"Patient selection for liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Management of pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of pain in patients with cirrhosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10007?source=see_link\">",
"     \"Management of pain in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Umbilical hernias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Umbilical hernias pose a management dilemma in patients with cirrhosis since they often develop in patients with severe liver disease and ascites who are at increased risk from complications from surgical repair. In a nationwide cohort study that compared the outcomes of abdominal wall hernia repairs in 1197 patients with cirrhosis to 20,831 patients without cirrhosis, patients with cirrhosis had a significantly higher incidence of ICU admissions (15.9 versus 6 percent), length of stay (5.4 days versus 3.7 days), morbidity (16.5 versus 13.8 percent), and mortality (2.5 versus 0.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the same time, observant management has been associated with severe complications including incarceration, spontaneous rupture, and evisceration, leading some authorities to recommend elective surgical repair [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/28-33\">",
"     28-33",
"    </a>",
"    ]. One report, for example, compared outcomes in 17 patients who underwent elective hernia repair and 13 patients who were managed conservatively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/33\">",
"     33",
"    </a>",
"    ]. Complications and recurrence occurred in 3 out of 17 and 4 out of 17 patients, respectively, who were managed by elective repair. In the 13 patients who were managed conservatively, 10 patients required surgery for incarceration, and two patients died [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Successful management using a variety of minimally invasive surgical techniques has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/33-37\">",
"     33-37",
"    </a>",
"    ]. However, clinical experience has tempered our enthusiasm for elective surgical repair. We have witnessed an unacceptably high complication and recurrence rate in our patients referred for elective repair [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17337/abstract/38\">",
"     38",
"    </a>",
"    ]. Liver transplant surgeons prefer to repair hernias at the time of transplant and not before because many have observed high postoperative morbidity and mortality when repair was performed before transplant.",
"   </p>",
"   <p>",
"    Thus, we have adopted the following approach.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with ruptured or incarcerated hernias are referred for immediate repair. However, if incarceration is detected early, it can sometimes be reduced.",
"     </li>",
"     <li>",
"      Patients with symptomatic hernias or those with marked thinning of the skin overlying the hernia sac (a sign of impending rupture), especially if there is weeping of fluid or an eschar on the apex of the hernia, are referred for elective repair.",
"     </li>",
"     <li>",
"      Patients with asymptomatic hernias are managed conservatively, with surgical correction of the hernia performed at the time of liver transplantation. The cornerstone of conservative management in asymptomatic patients with umbilical hernias is aggressive management of ascites.",
"      <span class=\"nowrap\">",
"       Elastic/Velcro",
"      </span>",
"      abdominal binders can also help reduce pain and minimize further enlargement of the hernia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=see_link\">",
"       \"Initial therapy of ascites in patients with cirrhosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35465?source=see_link\">",
"       \"Treatment of diuretic-resistant ascites in patients with cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/25/24979?source=see_link\">",
"       \"Patient information: Cirrhosis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/42/44706?source=see_link\">",
"       \"Patient information: Liver cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=see_link\">",
"       \"Patient information: Cirrhosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cirrhosis represents a late stage of progressive hepatic fibrosis, characterized by distortion of the hepatic architecture and the formation of regenerative nodules. Advanced cirrhosis is generally considered to be irreversible, while early stages may regress with specific treatments aimed at the underlying cause.",
"     </li>",
"     <li>",
"      Once a patient develops complications of cirrhosis, they are considered to have decompensated disease (",
"      <a class=\"graphic graphic_table graphicRef65667 \" href=\"UTD.htm?0/56/907\">",
"       table 1",
"      </a>",
"      ). The high morbidity and mortality of cirrhosis is secondary to these devastating complications. The quality of life and survival of patients with cirrhosis can be improved by the prevention and treatment of these complications. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis of cirrhosis is highly variable since it is influenced by a number of factors, including etiology, severity, presence of complications, and comorbid diseases. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major goals of treatment include slowing or reversing the progression of liver disease, preventing superimposed insults to the liver, preventing and treating the complications, and determining the appropriateness and optimal timing for liver transplantation. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)\"",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Vital and Health Statistics Series 13, No. 14.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/2\">",
"      Liao WC, Hou MC, Chang CJ, et al. Potential precipitating factors of esophageal variceal bleeding: a case-control study. Am J Gastroenterol 2011; 106:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/3\">",
"      Mumtaz K, Ahmed US, Abid S, et al. Precipitating factors and the outcome of hepatic encephalopathy in liver cirrhosis. J Coll Physicians Surg Pak 2010; 20:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/4\">",
"      Sundaram V, Shaikh OS. Hepatic encephalopathy: pathophysiology and emerging therapies. Med Clin North Am 2009; 93:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/5\">",
"      Berzigotti A, Garcia-Tsao G, Bosch J, et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology 2011; 54:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/6\">",
"      Bajaj JS, O'Leary JG, Reddy KR, et al. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology 2012; 56:2328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/7\">",
"      Smith JL, Graham DY. Variceal hemorrhage: a critical evaluation of survival analysis. Gastroenterology 1982; 82:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/8\">",
"      Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981; 80:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/9\">",
"      Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991; 100:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/10\">",
"      Zardi EM, Abbate A, Zardi DM, et al. Cirrhotic cardiomyopathy. J Am Coll Cardiol 2010; 56:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/11\">",
"      Abrams GA, Concato J, Fallon MB. Muscle cramps in patients with cirrhosis. Am J Gastroenterol 1996; 91:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/12\">",
"      Baskol M, Ozbakir O, Cokun R, et al. The role of serum zinc and other factors on the prevalence of muscle cramps in non-alcoholic cirrhotic patients. J Clin Gastroenterol 2004; 38:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/13\">",
"      Angeli P, Albino G, Carraro P, et al. Cirrhosis and muscle cramps: evidence of a causal relationship. Hepatology 1996; 23:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/14\">",
"      Konikoff F, Theodor E. Painful muscle cramps. A symptom of liver cirrhosis? J Clin Gastroenterol 1986; 8:669.",
"     </a>",
"    </li>",
"    <li>",
"     Child, CG, III, Turcotte, JG. Surgery and Portal Hypertension. In: The Liver and portal hypertension, Child, CG III (Eds), WB Saunders, Philadelphia 1964. p.50.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/16\">",
"      Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/17\">",
"      Mansour A, Watson W, Shayani V, Pickleman J. Abdominal operations in patients with cirrhosis: still a major surgical challenge. Surgery 1997; 122:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/18\">",
"      Garrison RN, Cryer HM, Howard DA, Polk HC Jr. Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis. Ann Surg 1984; 199:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/19\">",
"      Infante-Rivard C, Esnaola S, Villeneuve JP. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology 1987; 7:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/20\">",
"      Albers I, Hartmann H, Bircher J, Creutzfeldt W. Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol 1989; 24:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/21\">",
"      de Franchis R, Primignani M. Why do varices bleed? Gastroenterol Clin North Am 1992; 21:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/22\">",
"      Salpeter SR, Luo EJ, Malter DS, Stuart B. Systematic review of noncancer presentations with a median survival of 6 months or less. Am J Med 2012; 125:512.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/23\">",
"      Bonis PA, Friedman SL, Kaplan MM. Is liver fibrosis reversible? N Engl J Med 2001; 344:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/24\">",
"      H&eacute;zode C, Cast&eacute;ra L, Roudot-Thoraval F, et al. Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther 2011; 34:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/25\">",
"      Villa E, Camm&agrave; C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/26\">",
"      Amitrano L, Guardascione MA, Menchise A, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010; 44:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/27\">",
"      Carbonell AM, Wolfe LG, DeMaria EJ. Poor outcomes in cirrhosis-associated hernia repair: a nationwide cohort study of 32,033 patients. Hernia 2005; 9:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/28\">",
"      Trotter JF, Suhocki PV. Incarceration of umbilical hernia following transjugular intrahepatic portosystemic shunt for the treatment of ascites. Liver Transpl Surg 1999; 5:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/29\">",
"      Granese J, Valaulikar G, Khan M, Hardy H 3rd. Ruptured umbilical hernia in a case of alcoholic cirrhosis with massive ascites. Am Surg 2002; 68:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/30\">",
"      Podymow T, Sabbagh C, Turnbull J. Spontaneous paracentesis through an umbilical hernia. CMAJ 2003; 168:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/31\">",
"      Ginsburg BY, Sharma AN. Spontaneous rupture of an umbilical hernia with evisceration. J Emerg Med 2006; 30:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/32\">",
"      Choo EK, McElroy S. Spontaneous bowel evisceration in a patient with alcoholic cirrhosis and an umbilical hernia. J Emerg Med 2008; 34:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/33\">",
"      Marsman HA, Heisterkamp J, Halm JA, et al. Management in patients with liver cirrhosis and an umbilical hernia. Surgery 2007; 142:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/34\">",
"      Ozden I, Emre A, Bilge O, et al. Elective repair of abdominal wall hernias in decompensated cirrhosis. Hepatogastroenterology 1998; 45:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/35\">",
"      Sarit C, Eliezer A, Mizrahi S. Minimally invasive repair of recurrent strangulated umbilical hernia in cirrhotic patient with refractory ascites. Liver Transpl 2003; 9:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/36\">",
"      Melcher ML, Lobato RL, Wren SM. A novel technique to treat ruptured umbilical hernias in patients with liver cirrhosis and severe ascites. J Laparoendosc Adv Surg Tech A 2003; 13:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/37\">",
"      Belli G, D'Agostino A, Fantini C, et al. Laparoscopic incisional and umbilical hernia repair in cirrhotic patients. Surg Laparosc Endosc Percutan Tech 2006; 16:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17337/abstract/38\">",
"      Runyon BA, Juler GL. Natural history of repaired umbilical hernias in patients with and without ascites. Am J Gastroenterol 1985; 80:38.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1263 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-D9A34E86B4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_59_17337=[""].join("\n");
var outline_f16_59_17337=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ascites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Spontaneous bacterial peritonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233194597\">",
"      Hospital-acquired secondary infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Variceal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hepatopulmonary syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other pulmonary syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H124251188\">",
"      Cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hepatic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Portal vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Muscle cramps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Predictive models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H145979036\">",
"      Decompensated cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Slowing or reversing the progression of liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Preventing superimposed insults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Preventing complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Variceal bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Spontaneous bacterial peritonitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H233194589\">",
"      - Secondary infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Hepatic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H78564944\">",
"      - Portal vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Management of pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Umbilical hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/1263\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1263|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/16/38158\" title=\"figure 1\">",
"      Evolution of hepatic encephal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/37/12883\" title=\"figure 2\">",
"      Clinical features of hepatic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1263|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/56/907\" title=\"table 1\">",
"      Complications of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/0/13323\" title=\"table 2\">",
"      Child Turcotte classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/21/8540\" title=\"table 3\">",
"      Child Pugh classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/34/556\" title=\"table 4\">",
"      Precipitants of HE in cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=related_link\" title=\"calculator 1\">",
"      Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?18/2/18466?source=related_link\" title=\"calculator 2\">",
"      Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12) (SI units)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?27/26/28065?source=related_link\" title=\"calculator 3\">",
"      Calculator: Child Pugh classification for severity of liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?28/28/29121?source=related_link\" title=\"calculator 4\">",
"      Calculator: Child Pugh classification for severity of liver disease (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12858?source=related_link\">",
"      Assessing surgical risk in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=related_link\">",
"      Clinical features and diagnosis of primary hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34153?source=related_link\">",
"      Clinical manifestations and diagnosis of hepatic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/0/7172?source=related_link\">",
"      Clinical manifestations of spontaneous bacterial peritonitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=related_link\">",
"      Coagulation abnormalities in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12296?source=related_link\">",
"      Diagnosis of spontaneous bacterial peritonitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=related_link\">",
"      Diagnostic approach to the patient with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13242?source=related_link\">",
"      Emerging therapies for hepatic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14010?source=related_link\">",
"      Evaluation of adults with ascites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4346?source=related_link\">",
"      Hepatic encephalopathy in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30263?source=related_link\">",
"      Hepatic hydrothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/35/3640?source=related_link\">",
"      Hepatopulmonary syndrome: Prevalence, causes, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=related_link\">",
"      Hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9978?source=related_link\">",
"      High-output heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8569?source=related_link\">",
"      Immunizations for patients with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=related_link\">",
"      Initial therapy of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10007?source=related_link\">",
"      Management of pain in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4711?source=related_link\">",
"      Nocturnal leg cramps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29801?source=related_link\">",
"      Palliative care: Benefits, services, and models of care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21527?source=related_link\">",
"      Pathogenesis of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34197?source=related_link\">",
"      Pathogenesis of spontaneous bacterial peritonitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=related_link\">",
"      Patient information: Cirrhosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/25/24979?source=related_link\">",
"      Patient information: Cirrhosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/42/44706?source=related_link\">",
"      Patient information: Liver cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=related_link\">",
"      Patient selection for liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35064?source=related_link\">",
"      Portopulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21446?source=related_link\">",
"      Prediction of variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=related_link\">",
"      Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=related_link\">",
"      Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22104?source=related_link\">",
"      Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4121?source=related_link\">",
"      Treatment and prophylaxis of spontaneous bacterial peritonitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40058?source=related_link\">",
"      Treatment of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35465?source=related_link\">",
"      Treatment of diuretic-resistant ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_59_17338="Prevention and control of methicillin-resistant Staphylococcus aureus in adults";
var content_f16_59_17338=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention and control of methicillin-resistant Staphylococcus aureus in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/59/17338/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/59/17338/contributors\">",
"     Anthony Harris, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/59/17338/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/59/17338/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/59/17338/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/59/17338/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/59/17338/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention and control of methicillin-resistant Staphylococcus aureus (MRSA) cross-infection is among the most important challenges of infection control. The success of MRSA control has varied substantially with different strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Some European countries have managed to contain MRSA at a low prevalence using active surveillance cultures and contact precautions, with or without decolonization (examples include the Netherlands, Finland, and France) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Other countries have struggled to control MRSA epidemics (examples include Germany and Canada) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The countries with greatest MRSA prevalence include the United States and Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/2,9,10\">",
"     2,9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=see_link\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to prevention and control of MRSA will be reviewed here. Issues related to the treatment and epidemiology (including transmission) of these infections are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=see_link\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=see_link\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15575?source=see_link\">",
"     \"Microbiology of methicillin-resistant Staphylococcus aureus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SURVEILLANCE AND PRECAUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active surveillance cultures (ASC) facilitate identification of patients with MRSA colonization to be placed on contact precautions with the goal of minimizing MRSA spread to other patients. Because patients with evidence of MRSA in routine clinical specimens represent only a small fraction of the reservoir for spread of antibiotic-resistant pathogens, active surveillance specimens identify the reservoir of asymptomatic, colonized patients who would otherwise go unrecognized and unisolated [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While most agree that ASC with contact isolation is appropriate in the setting of an outbreak, the role of ASC for routine surveillance screening is a controversial issue of ongoing debate [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]. Points of contention include the overall efficacy of such interventions and the judicious use of health care resources.",
"   </p>",
"   <p>",
"    Rapid whole-genome sequencing is an alternative method that may be useful for outbreak investigation, but is not widely available [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active surveillance cultures (ASC) appear to be most useful in the setting of hospital outbreaks and among patients at high risk for MRSA infection, such as patients in intensive care units (ICUs), immunocompromised patients, long-term care facility residents, and patients on hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/11,13,19-22\">",
"     11,13,19-22",
"    </a>",
"    ]. Universal active surveillance cultures outside of outbreaks may be useful in certain circumstances, although the efficacy for this practice is less clear.",
"   </p>",
"   <p>",
"    Supporting data from studies of ASC in the setting of an outbreak and in an ICU are summarized below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of a hospital MRSA outbreak, 40 percent of all hospital-acquired S. aureus bacteremias and 49 percent of all S. aureus surgical-site infections were caused by one strain of MRSA [",
"      <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/12\">",
"       12",
"      </a>",
"      ]. After implementation of active surveillance cultures to identify and isolate previously unrecognized patients colonized by the outbreak strain, the outbreak was curtailed over a 12-month period.",
"     </li>",
"     <li>",
"      During an MRSA outbreak in a neonatal intensive care unit, the rate of transmission from patients colonized with MRSA who had been identified by use of active surveillance cultures and placed on contact precautions (determined based on proximity in time and space and shared exposure to caregivers) was compared with the rate of transmission from patients colonized with MRSA but not yet identified and thus using universal precautions only [",
"      <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/19\">",
"       19",
"      </a>",
"      ]. The rate of transmission was 15.6-fold higher for patients not yet recognized to be colonized.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the efficacy of universal active surveillance cultures is uncertain, as illustrated by the following studies with conflicting conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a cluster randomized trial involving more than 9000 patients admitted to 18 intensive care units, use of MRSA surveillance cultures and expanded use of barrier precautions (universal glove precautions while awaiting active surveillance culture results) were not effective in reducing transmission of MRSA compared with existing practice [",
"      <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/25\">",
"       25",
"      </a>",
"      ]. This finding was surprising given that surveillance cultures identified a sizable subgroup of colonized patients who were not otherwise recognized. The authors hypothesized that additional interventions such as antiseptic bathing and improved environmental decontamination may be needed. Limitations of the study included the long turn-around time of the active surveillance cultures and omission of gowns as part of the barrier precautions.",
"     </li>",
"     <li>",
"      In a Veterans Affairs (VA) system-wide quality improvement initiative including nearly 2 million patients in 150 hospitals, a MRSA &ldquo;bundle&rdquo; program (including universal MRSA surveillance, contact precautions for colonized or infected patients, hand hygiene, and institutional culture change) was implemented [",
"      <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/26\">",
"       26",
"      </a>",
"      ]. This program was temporally associated with a reduction in the rate of healthcare associated MRSA infection in intensive care units by 62 percent (from 1.64 to 0.62 infections per 1000 patient-days) and general units by 45 percent (from 0.47 to 0.26 infections per 1000 patient-days). However, as this study did not include control groups, it was not possible to determine whether MRSA surveillance was causally related to the observed drop in rates.",
"      <br/>",
"      <br/>",
"      Subsequently a mathematical model demonstrated that the universal screen and isolate strategy can have contributed only marginally to the reduction in infections, since transmission rates before bundle implementation were already low and most patients with MRSA colonization were already colonized at admission [",
"      <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Advocates of active surveillance have pointed to its success among several European countries where MRSA has been contained at a low prevalence (examples include the Netherlands, Finland, and France) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/4,5,28,29\">",
"     4,5,28,29",
"    </a>",
"    ]. These strategies involved a multifaceted approach including surveillance, contact isolation, health care worker screening with decolonization, and closing units for comprehensive screening and cleaning when warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. Given this combination of interventions, it is not always certain which intervention or which combination of interventions is required for MRSA control. Therefore, extrapolating these experiences to other health care settings with variable MRSA prevalence and other factors may be difficult.",
"   </p>",
"   <p>",
"    Moreover, the impact of community-associated MRSA (CA-MRSA) on the feasibility of hospital-based active surveillance cultures is uncertain; strategies focusing on nosocomial transmission may be undermined by patients admitted to the hospital with MRSA acquired in the community [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'In the community'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cost effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of active surveillance cultures has been shown to be cost-effective during ICU outbreaks as well as in some high-risk MRSA transmission settings, as illustrated by the following examples [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A neonatal ICU MRSA outbreak was curtailed with weekly surveillance cultures and isolation of infants with MRSA colonization or infection, and the cost was 19- to 27-fold less than the attributable cost of MRSA bloodstream infections in a hospital where surveillance cultures were not collected [",
"      <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an ICU with MRSA prevalence of up to 4 percent, active surveillance was cost-effective, even if only a small proportion of MRSA infections were prevented [",
"      <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the cost-effectiveness of routine surveillance screening has not been evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/15,25\">",
"     15,25",
"    </a>",
"    ]. Infection control practitioners have also cited concerns regarding limited numbers of single-patient rooms, limited clinical microbiology resources for processing surveillance specimens, and the importance of flexibility in resource allocation to keep pace with unexpected changes in local epidemiologic trends [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/15\">",
"     15",
"    </a>",
"    ]. There is also concern that patients on contact isolation receive reduced attention from health care workers; it has been observed that such patients are more likely to experience adverse events than those not on contact isolation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/40-44\">",
"     40-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Institutions performing screening tests should establish clear policies regarding how the results will be used to make decisions about contact precautions, cohorting and decolonization procedures. Educational programming about adherence to the principles discussed here is imperative for patients, health care workers, environmental cleaners and other hospital personnel (including social workers, dietary service workers and administrative personnel). Information should be provided to patients and families to help alleviate fears and concerns; printed materials may be useful and can also help ensure consistent messages.",
"   </p>",
"   <p>",
"    MRSA colonization status should be noted in the hospital record so that appropriate precautions can be arranged promptly if colonized patients require repeat admission [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/45\">",
"     45",
"    </a>",
"    ]. This is important because MRSA colonization can persist for months; in a prospective study of 78 previously colonized patients readmitted to the same facility &ge;3 months later, colonization persisted in 40 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active surveillance samples should be obtained from the anterior nares. Although most favor a single sample site, some advocate sampling at least one additional site [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. This is because although the anterior nares are a frequent site of MRSA carriage (positive in 73 to 93 percent of carriers), nasal colonization has not been universally found among MRSA-positive patients with implanted devices, for example, and the rectum may be an important reservoir among those with CA-MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. Throat cultures have been shown to detect MRSA with sensitivity equal to or greater than that of nasal cultures and may be used in addition to or as an alternative to nasal cultures. Areas of skin breakdown should also be sampled for MRSA, if present.",
"   </p>",
"   <p>",
"    Laboratory evaluation of surveillance samples is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31654?source=see_link\">",
"     \"Rapid detection of methicillin-resistant Staphylococcus aureus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal role for active surveillance is not known and there is insufficient evidence for a single routine approach. Experts agree that active surveillance should be performed for all patients in the setting of an MRSA outbreak; in addition, many favor active surveillance for patients at high risk for MRSA carriage [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/50\">",
"     50",
"    </a>",
"    ]. Such patients include [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/14,51-53\">",
"     14,51-53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with history of MRSA colonization (such patients should be isolated initially pending surveillance testing results)",
"     </li>",
"     <li>",
"      Patients in intensive care",
"     </li>",
"     <li>",
"      Patients hospitalized in the previous 12 months",
"     </li>",
"     <li>",
"      Patients who have had extensive contact with health care system (such as nursing home residents, patients receiving dialysis or patients receiving outpatient infusion therapy)",
"     </li>",
"     <li>",
"      Patients who have received antibiotic therapy in the last three months",
"     </li>",
"     <li>",
"      Patients with skin or soft tissue infection at admission",
"     </li>",
"     <li>",
"      Patients with additional risk factors for MRSA as outlined in detail separately (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=see_link\">",
"       \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It may be prudent for facilities with high prevalence of MRSA on active surveillance to consider instituting facility-wide surveillance to identify all colonized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/49\">",
"     49",
"    </a>",
"    ]. For patients with initial negative surveillance cultures who require extended hospitalization in units with ongoing problems with MRSA transmission, some favor weekly surveillance cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basic principles regarding contact precautions are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link&amp;anchor=H11#H11\">",
"     \"General principles of infection control\", section on 'Contact precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple studies have demonstrated the efficacy of contact precautions for reducing spread of MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/13,19,56\">",
"     13,19,56",
"    </a>",
"    ]. During an MRSA outbreak in a neonatal intensive care unit, the rate of transmission from patients colonized with MRSA who had been identified by use of active surveillance cultures and placed on contact precautions (determined based on proximity in time and space and shared exposure to caregivers) was compared with the rate of transmission from patients colonized with MRSA but not yet identified and thus using universal precautions only [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/19\">",
"     19",
"    </a>",
"    ]. The rate of transmission was 15.6-fold higher for patients not yet recognized to be colonized.",
"   </p>",
"   <p>",
"    Patients colonized or infected with MRSA can be cohorted with other MRSA patients. However, if eradication will be used as an adjunctive measure, patients with MRSA isolates that are potentially eradicable (given known susceptibility to drugs useful for eradication such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ) should not be cohorted with patients whose MRSA isolates are resistant to these drugs. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Decolonization'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although masks are not included in the CDC definition for contact precautions, masks may offer some benefit for reducing colonization among health care workers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/13,57\">",
"     13,57",
"    </a>",
"    ]. If their routine use is not implemented, the most appropriate setting for masks is probably in the care of patients with active pulmonary infection due to MRSA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATIENT BATHING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient bathing with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    has been shown to be useful for reducing MRSA colonization and infection; this issue is discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link&amp;anchor=H3992580#H3992580\">",
"     \"General principles of infection control\", section on 'Patient bathing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DECOLONIZATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of decolonization in the control of MRSA spread is uncertain. Although MRSA nasal colonization appears to precede infection, asymptomatic nasal carriage is not always identifiable in the setting of MRSA infections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/58\">",
"     58",
"    </a>",
"    ]. Other potentially important roles in transmission include impaired host defenses and contact with skin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fomites [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/59\">",
"     59",
"    </a>",
"    ]. Thus, further study of S. aureus pathogenesis will be important for optimal prevention measures.",
"   </p>",
"   <p>",
"    Decolonization does not appear to be consistently effective for eliminating MRSA carriage [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/23,24,60,61\">",
"     23,24,60,61",
"    </a>",
"    ]. A systematic review of six trials (published prior to 2003) including 384 participants concluded that the available evidence is inadequate to recommend the use of topical or systemic agents to eliminate MRSA colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/60\">",
"     60",
"    </a>",
"    ]. Decolonization has also been studied in the context of large studies including other infection control measures, so it can be difficult to discern the effect of this particular intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Furthermore, emergence of resistance to agents used for decolonization will limit the utility of such protocols.",
"   </p>",
"   <p>",
"    Nonetheless, many clinicians favor attempting MRSA decolonization, and there are many uncertainties about the optimal approach. Should decolonization be pursued only in the setting of MRSA outbreaks, or as a component of routine management of MRSA infection? Should it be used for prevention of MRSA infection among hospitalized patients, in the community, or both? Might widespread decolonization lead to evolution and spread of increasingly resistant antibiotic-resistant strains?",
"   </p>",
"   <p>",
"    Most of the available data have been collected in the hospital setting; less is known about the optimal role of decolonization in the community. Studies have evaluated the role of decolonization among patients and health care workers, although the limited durability of MRSA decolonization complicates determination of its optimal role among these groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6351471\">",
"    <span class=\"h3\">",
"     Patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decolonization of hospitalized patients may reduce the incidence of MRSA infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/62\">",
"     62",
"    </a>",
"    ], although its efficacy is difficult to discern given the impracticality of designing a randomized study of this intervention without incorporation of other infection control measures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/23,63\">",
"     23,63",
"    </a>",
"    ]. An observational study of intranasal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    baths in an intensive care unit did demonstrate a reduction in the incidence of nosocomial MRSA infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decolonization of known S. aureus carriers undergoing surgery may be warranted; further study is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. One cohort study comparing MRSA wound infection rates following cardiothoracic surgery before and after a quality improvement program demonstrated reduction in postoperative MRSA infections by 93 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/67\">",
"     67",
"    </a>",
"    ]. The interventions included preoperative screening for MRSA colonization, administration of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    prophylaxis for identified carriers, administration of intranasal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    calcium ointment to all patients for five days beginning the day before surgery, and application of mupirocin to chest tube sites at the time of removal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Health care workers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decolonization of health care workers (HCWs) may be a useful adjunctive measure to control the spread of MRSA, although it is rarely necessary or advisable except as a last resort after other standard infection control measures are implemented [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. This was illustrated in a study of 68 HCWs with S. aureus nasal carriage who received topical treatment with intranasal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    ointment twice daily for five days or placebo; treatment was associated with a 91 percent reduction in the prevalence of S. aureus carriage [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/68\">",
"     68",
"    </a>",
"    ]. However, recolonization was observed within four weeks in 26 percent of cases, and about half of the decolonized individuals had become recolonized after six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Durability",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eradication of MRSA carriage is not always successful or durable [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/13\">",
"     13",
"    </a>",
"    ]. Recolonization rates at 12 months following treatment ranges from 50 to 75 percent among health care workers and patients undergoing peritoneal dialysis, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/70\">",
"     70",
"    </a>",
"    ]. Short-term recolonization rates are similar; 56 percent four months in patients undergoing hemodialysis and 71 percent at 2.5 months in patients with HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal regimen and duration of therapy for eradicating MRSA colonization is uncertain. Some favor topical therapy alone, while others favor topical therapy together with systemic oral antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Prolonged use is not appropriate as it has been associated with evolution and spread of antibiotic-resistant strains, loss of valuable therapeutic agents for subsequent treatment of infection, and adverse drug effects [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/73,75-77\">",
"     73,75-77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Topical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    (for eradication of nasal colonization) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    baths [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/73,78,79\">",
"     73,78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     Mupirocin",
"    </a>",
"    (applied to anterior nares twice daily for five to seven days) inhibits bacterial protein and RNA synthesis. The topical form has minimal toxicity and no structural similarity with existing systemic antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. However, mupirocin resistance has been reported (24 percent of MRSA isolates in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/73,82-84\">",
"     73,82-84",
"    </a>",
"    ]. The gene for high-level mupirocin resistance, mupA, has been found on a plasmid in USA300 MRSA clones, suggesting that the future utility of this drug may be limited, since this clone has been implicated in many community-associated MRSA infections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Thus far no FDA breakpoints have been established for mupirocin susceptibility testing, and commercial tests are limited.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    monotherapy for decolonization is uncertain. There have been some reports of successful decolonization using nasal mupirocin alone for a variety of patient populations, including patients undergoing dialysis, patients with HIV infection, nursing home residents, and liver transplant candidates (95, 88, 85 and 87 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. However, a randomized controlled trial among 3447 military personnel failed to demonstrate a difference in rate of infection between those decolonized with mupirocin versus placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/89\">",
"     89",
"    </a>",
"    ]. The reasons for the variability of mupirocin efficacy among different demographic groups in the setting of mupirocin susceptibility are not fully understood.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     Chlorhexidine",
"    </a>",
"    binds the bacterial cell wall, altering osmotic equilibrium [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/90\">",
"     90",
"    </a>",
"    ]. Whole-body washing with chlorhexidine can reduce MRSA skin colonization, but eradication has been achieved only in combination with nasal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    , with or without systemic antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/73,78,79,91\">",
"     73,78,79,91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;No clinical trials have evaluated the role of oral antimicrobial agents for management of recurrent MRSA infections. A Cochrane review found no benefit of oral antibiotics for eradication of MRSA colonization among patients in the health care setting; the impact of oral antibiotics on rates of infection was not studied [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/60\">",
"     60",
"    </a>",
"    ]. Oral antimicrobials are not routinely recommended for decolonization; they should only be considered in patients who continue to have recurrent MRSA infection in spite of other measures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If oral antibiotics are prescribed for decolonization, the optimal regimen and duration is unknown. A",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    -based regimen (eg, rifampin in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ) in short courses (5 to 10 days) is suggested to minimize potential for development of resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/92\">",
"     92",
"    </a>",
"    ]. The oral regimen should be offered in conjunction with topical therapy with reinforcement of hygiene measures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Topical therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H21\">",
"     'In the community'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Suggested approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, there is insufficient evidence to support routine MRSA decolonization. However, decolonization may be appropriate in the setting of MRSA outbreaks, particularly if there is epidemiologic evidence pointing to transmission by one or more healthcare workers or among a specific population or household. In addition, decolonization may be reasonable for patients with multiple documented recurrences of MRSA infection, or if ongoing transmission is occurring among household members or other close contacts despite optimizing hygiene measures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. Decolonization in surgical patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10805?source=see_link\">",
"     \"Controversies in control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If decolonization is pursued, we favor a 5 to 10 day course of therapy with the following topical agents [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/73,92,94\">",
"     73,92,94",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       Chlorhexidine gluconate",
"      </a>",
"      daily washes (2 or 4 percent solution)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"       Mupirocin",
"      </a>",
"      ointment (2 percent) applied to nares with a cotton-tipped applicator two to three times daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Routine surveillance cultures following decolonization are not necessary in the absence of active infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/92\">",
"     92",
"    </a>",
"    ]. If repeat infection occurs and repeat decolonization is warranted, it is reasonable to consider a repeat course of decolonization including topical agents as outlined above, together with systemic agents as discussed in the preceding section. However, the efficacy of successful decolonization following a failed initial attempt is relatively low. In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    resistance has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     WOUND CARE AND HAND HYGIENE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Draining wounds should be kept covered with clean, dry bandages. Good personal hygiene should be maintained with cleaning of hands with soap and water or an alcohol-based hand gel, particularly after touching infected skin or an item that has directly contacted a draining wound [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/92\">",
"     92",
"    </a>",
"    ]. Basic principles regarding hand hygiene are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link&amp;anchor=H3#H3\">",
"     \"General principles of infection control\", section on 'Hand hygiene'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hand hygiene is an important factor in controlling the transmission of healthcare-associated infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. This was illustrated in a study in which implementation of a hand-hygiene campaign led to an increase in the rate of hand hygiene compliance (48 to 66 percent) with a concomitant decrease in the rate of MRSA transmission (2.16 to 0.93 episodes per 10,000 patient-days) and the overall rate of healthcare-associated infections (16.9 to 9.9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/97\">",
"     97",
"    </a>",
"    ]. Hand hygiene must be incorporated into comprehensive infection control programs including multiple components of active surveillance cultures, use of contact precautions and antibiotic control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ENVIRONMENTAL CLEANING",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRSA can survive on some surfaces for hours, days or months; viability depends on a variety of factors including temperature, humidity, the number of organisms present, and the type of surface (porous or nonporous).",
"   </p>",
"   <p>",
"    MRSA is sensitive to routinely used hospital disinfectants, and it is essential that meticulous cleaning of patient care surfaces be performed for control of environmental contamination with MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/13,98,99\">",
"     13,98,99",
"    </a>",
"    ]. Environmental services personnel should be included as an integral part of the infection control team. Checklists for cleaning frequently touched patient care surfaces (such as bed controls, light switches, doorknobs, etc) can be useful for reinforcing consistency [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/50\">",
"     50",
"    </a>",
"    ]. Medical equipment should be dedicated to a single patient when possible, to avoid transfer of pathogens via fomites. Equipment that must be shared should be cleaned and disinfected before use for another patient [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultraviolet markers may be useful for monitoring thoroughness of room cleaning [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/100-102\">",
"     100-102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC STEWARDSHIP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy must be administered prudently (eg, at the correct dose and for the correct duration), as inappropriate or excessive antibiotic use can lead to selection of resistant organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/103-105\">",
"     103-105",
"    </a>",
"    ]. The risk of MRSA colonization has been correlated with the frequency and duration of prior antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. Several studies have documented a higher risk of MRSA colonization following therapy with fluoroquinolones in particular [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/108-110\">",
"     108-110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reductions in the use of certain antibiotics can reduce the incidence of MRSA infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/111-113\">",
"     111-113",
"    </a>",
"    ]. This was illustrated in a retrospective review in which the rate of MRSA isolation decreased at a university hospital following a switch in the perioperative prophylaxis agent from a third-generation to a first-generation cephalosporin [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/111\">",
"     111",
"    </a>",
"    ]. Another report described a significant reduction in the monthly number of patients with MRSA (from 21.9 to 17.2 patients per 1000 discharges) following formulary alterations resulting in decreased usage of cephalosporins, imipenem,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    and increased usage of",
"    <span class=\"nowrap\">",
"     beta-lactam/beta-lactamase-inhibitor",
"    </span>",
"    antibiotics.",
"   </p>",
"   <p>",
"    However, it is important to note that altering an antibiotic formulary can in turn lead to emergence of other resistant pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/112,114\">",
"     112,114",
"    </a>",
"    ]. Formulary restriction may be beneficial in the setting of a nosocomial outbreak, although its long-term beneficial impact on resistance has not been established.",
"   </p>",
"   <p>",
"    Use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    for MRSA decolonization can lead to resistance to these agents. Combined mupirocin and chlorhexidine resistance increases the risk of persistent MRSA carriage after decolonization therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/95\">",
"     95",
"    </a>",
"    ]. In regions where the use of these agents is widespread, monitoring for resistance and loss of clinical effectiveness is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     IN THE COMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to implementation of control measures in hospitals, considerations for prevention of MRSA spread in the community include hand hygiene, care in contacting potentially contaminated surfaces (",
"    <a class=\"graphic graphic_table graphicRef53504 \" href=\"UTD.htm?5/9/5275\">",
"     table 1",
"    </a>",
"    ), and the role of decolonization [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/53,115,116\">",
"     53,115,116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hand hygiene is as important in the community as in the hospital. Hands should be cleaned thoroughly with soap and water or an alcohol-based hand sanitizer. The hands should be cleaned immediately after touching the skin or any item that has come in direct contact with a draining wound.",
"   </p>",
"   <p>",
"    Wounds that are draining should be kept covered with clean, dry bandages. Patients with open wounds should not participate in activities involving skin-to-skin contact with others (such as athletics) until wounds are fully healed. Individuals should avoid sharing personal items that may become contaminated with wound drainage, such as towels, clothing, bedding, bar soap, razors, or athletic equipment that touches the skin. Clothing that comes into contact with wound drainage should be laundered and dried thoroughly. Environmental surfaces with which multiple individuals have bare skin contact should be cleaned with an over-the-counter cleaner that specifies activity against S. aureus and is suitable for the type of surface being cleaned.",
"   </p>",
"   <p>",
"    Decolonizing patients and their household contacts may be useful for reducing the incidence of MRSA. In a study of 51 families of patients with MRSA colonization or infection, for example, household contacts with identical MRSA strains were identified in 43 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/117\">",
"     117",
"    </a>",
"    ]. Family members of MRSA carriers may be an important reservoir of MRSA in the community. In addition, cross-transmission of MRSA between humans and their pets has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?16/59/17338/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Decolonization'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/4/22595?source=see_link\">",
"       \"Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Active surveillance cultures (ASC) identify the reservoir of asymptomatic, colonized patients to be placed on contact precautions with the goal of minimizing MRSA spread to other patients. While most agree that ASC with contact isolation is appropriate in the setting of an outbreak, the role of ASC for routine surveillance screening is a controversial issue of ongoing debate. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of active surveillance cultures has been shown to be cost-effective during ICU outbreaks and in high-risk MRSA transmission settings, although the cost-effectiveness of routine surveillance screening is not known. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cost effectiveness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Methods for surveillance and precautions are outlined in detail above. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Methods'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that MRSA decolonization not be performed in the routine management of MRSA infections (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Decolonization does not appear to be consistently effective for eliminating MRSA carriage, and emergence of resistance to agents used for decolonization will limit the utility of such protocols. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Decolonization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest performing decolonization in the setting of an MRSA outbreak, particularly if there is epidemiologic evidence pointing to transmission by one or more healthcare workers or among a specific patient population (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Regimens are as outlined above. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Regimens'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Suggested approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional important components for MRSA prevention and control include hand hygiene, attention to environmental cleaning and prudent antibiotic use both in the hospital and in the community, as outlined above. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Wound care and hand hygiene'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Environmental cleaning'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Antibiotic stewardship'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'In the community'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/1\">",
"      Harbarth S, Pittet D. MRSA--a European currency of infection control. QJM 1998; 91:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/2\">",
"      Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32 Suppl 2:S114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/3\">",
"      Harbarth S, Albrich W, Goldmann DA, Huebner J. Control of multiply resistant cocci: do international comparisons help? Lancet Infect Dis 2001; 1:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/4\">",
"      Vriens M, Blok H, Fluit A, et al. Costs associated with a strict policy to eradicate methicillin-resistant Staphylococcus aureus in a Dutch University Medical Center: a 10-year survey. Eur J Clin Microbiol Infect Dis 2002; 21:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/5\">",
"      Kotilainen P, Routamaa M, Peltonen R, et al. Elimination of epidemic methicillin-resistant Staphylococcus aureus from a university hospital and district institutions, Finland. Emerg Infect Dis 2003; 9:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/6\">",
"      Simor AE, Ofner-Agostini M, Bryce E, et al. The evolution of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 5 years of national surveillance. CMAJ 2001; 165:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/7\">",
"      Afif W, Huor P, Brassard P, Loo VG. Compliance with methicillin-resistant Staphylococcus aureus precautions in a teaching hospital. Am J Infect Control 2002; 30:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/8\">",
"      Gastmeier P, Geffers C, Sohr D, et al. [Surveillance of nosocomial infections in intensive care units. Current data and interpretations]. Wien Klin Wochenschr 2003; 115:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/9\">",
"      National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002, issued August 2002. Am J Infect Control 2002; 30:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/10\">",
"      Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001; 7:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/11\">",
"      Shitrit P, Gottesman BS, Katzir M, et al. Active surveillance for methicillin-resistant Staphylococcus aureus (MRSA) decreases the incidence of MRSA bacteremia. Infect Control Hosp Epidemiol 2006; 27:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/12\">",
"      Thompson RL, Cabezudo I, Wenzel RP. Epidemiology of nosocomial infections caused by methicillin-resistant Staphylococcus aureus. Ann Intern Med 1982; 97:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/13\">",
"      Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003; 24:362.",
"     </a>",
"    </li>",
"    <li>",
"     Siegel JD, et al. Management of multidrug resistant organisms in healthcare settings 2006. Healthcare Infection Control Practices Advisory Committee. Available at: file://www.cdc.gov/ncidod/dhqp/pdf/ar/mdroGuideline2006.pdf (Accessed on April 14, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/15\">",
"      Weber SG, Huang SS, Oriola S, et al. Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: position statement from the Joint SHEA and APIC Task Force. Infect Control Hosp Epidemiol 2007; 28:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/16\">",
"      McGinigle KL, Gourlay ML, Buchanan IB. The use of active surveillance cultures in adult intensive care units to reduce methicillin-resistant Staphylococcus aureus-related morbidity, mortality, and costs: a systematic review. Clin Infect Dis 2008; 46:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/17\">",
"      Chaberny IF, Schwab F, Ziesing S, et al. Impact of routine surgical ward and intensive care unit admission surveillance cultures on hospital-wide nosocomial methicillin-resistant Staphylococcus aureus infections in a university hospital: an interrupted time-series analysis. J Antimicrob Chemother 2008; 62:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/18\">",
"      K&ouml;ser CU, Holden MT, Ellington MJ, et al. Rapid whole-genome sequencing for investigation of a neonatal MRSA outbreak. N Engl J Med 2012; 366:2267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/19\">",
"      Jernigan JA, Titus MG, Gr&ouml;schel DH, et al. Effectiveness of contact isolation during a hospital outbreak of methicillin-resistant Staphylococcus aureus. Am J Epidemiol 1996; 143:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/20\">",
"      Wernitz MH, Swidsinski S, Weist K, et al. Effectiveness of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers at hospital admission to prevent hospital-acquired MRSA infections. Clin Microbiol Infect 2005; 11:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/21\">",
"      Huang SS, Yokoe DS, Hinrichsen VL, et al. Impact of routine intensive care unit surveillance cultures and resultant barrier precautions on hospital-wide methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2006; 43:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/22\">",
"      Khoury J, Jones M, Grim A, et al. Eradication of methicillin-resistant Staphylococcus aureus from a neonatal intensive care unit by active surveillance and aggressive infection control measures. Infect Control Hosp Epidemiol 2005; 26:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/23\">",
"      Harbarth S, Fankhauser C, Schrenzel J, et al. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 2008; 299:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/24\">",
"      Robicsek A, Beaumont JL, Paule SM, et al. Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med 2008; 148:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/25\">",
"      Huskins WC, Huckabee CM, O'Grady NP, et al. Intervention to reduce transmission of resistant bacteria in intensive care. N Engl J Med 2011; 364:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/26\">",
"      Jain R, Kralovic SM, Evans ME, et al. Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections. N Engl J Med 2011; 364:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/27\">",
"      Gurieva T, Bootsma MC, Bonten MJ. Successful Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections revisited. Clin Infect Dis 2012; 54:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/28\">",
"      Harbarth S, Pittet D. Control of nosocomial methicillin-resistant Staphylococcus aureus: where shall we send our hospital director next time? Infect Control Hosp Epidemiol 2003; 24:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/29\">",
"      van Trijp MJ, Melles DC, Hendriks WD, et al. Successful control of widespread methicillin-resistant Staphylococcus aureus colonization and infection in a large teaching hospital in the Netherlands. Infect Control Hosp Epidemiol 2007; 28:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/30\">",
"      Pan A, Carnevale G, Catenazzi P, et al. Trends in methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: effect of the MRSA \"search and isolate\" strategy in a hospital in Italy with hyperendemic MRSA. Infect Control Hosp Epidemiol 2005; 26:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/31\">",
"      Verhoef J, Beaujean D, Blok H, et al. A Dutch approach to methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 1999; 18:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/32\">",
"      Vandenbroucke-Grauls CM. Methicillin-resistant Staphylococcus aureus control in hospitals: the Dutch experience. Infect Control Hosp Epidemiol 1996; 17:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/33\">",
"      Kluytmans-Vandenbergh MF, Kluytmans JA, Voss A. Dutch guideline for preventing nosocomial transmission of highly resistant microorganisms (HRMO). Infection 2005; 33:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/34\">",
"      King MD, Humphrey BJ, Wang YF, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006; 144:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/35\">",
"      Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006; 42:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/36\">",
"      Rubinovitch B, Pittet D. Screening for methicillin-resistant Staphylococcus aureus in the endemic hospital: what have we learned? J Hosp Infect 2001; 47:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/37\">",
"      Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C. Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA 1999; 282:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/38\">",
"      Papia G, Louie M, Tralla A, et al. Screening high-risk patients for methicillin-resistant Staphylococcus aureus on admission to the hospital: is it cost effective? Infect Control Hosp Epidemiol 1999; 20:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/39\">",
"      Karchmer TB, Durbin LJ, Simonton BM, Farr BM. Cost-effectiveness of active surveillance cultures and contact/droplet precautions for control of methicillin-resistant Staphylococcus aureus. J Hosp Infect 2002; 51:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/40\">",
"      Stelfox HT, Bates DW, Redelmeier DA. Safety of patients isolated for infection control. JAMA 2003; 290:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/41\">",
"      Evans HL, Shaffer MM, Hughes MG, et al. Contact isolation in surgical patients: a barrier to care? Surgery 2003; 134:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/42\">",
"      Kirkland KB, Weinstein JM. Adverse effects of contact isolation. Lancet 1999; 354:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/43\">",
"      Saint S, Higgins LA, Nallamothu BK, Chenoweth C. Do physicians examine patients in contact isolation less frequently? A brief report. Am J Infect Control 2003; 31:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/44\">",
"      Morgan DJ, Diekema DJ, Sepkowitz K, Perencevich EN. Adverse outcomes associated with Contact Precautions: a review of the literature. Am J Infect Control 2009; 37:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/45\">",
"      Pittet D, Safran E, Harbarth S, et al. Automatic alerts for methicillin-resistant Staphylococcus aureus surveillance and control: role of a hospital information system. Infect Control Hosp Epidemiol 1996; 17:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/46\">",
"      Scanvic A, Denic L, Gaillon S, et al. Duration of colonization by methicillin-resistant Staphylococcus aureus after hospital discharge and risk factors for prolonged carriage. Clin Infect Dis 2001; 32:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/47\">",
"      Sanford MD, Widmer AF, Bale MJ, et al. Efficient detection and long-term persistence of the carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1994; 19:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/48\">",
"      Eveillard M, de Lassence A, Lancien E, et al. Evaluation of a strategy of screening multiple anatomical sites for methicillin-resistant Staphylococcus aureus at admission to a teaching hospital. Infect Control Hosp Epidemiol 2006; 27:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/49\">",
"      Huang SS, Rifas-Shiman SL, Warren DK, et al. Improving methicillin-resistant Staphylococcus aureus surveillance and reporting in intensive care units. J Infect Dis 2007; 195:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/50\">",
"      Peterson LR, Hacek DM, Robicsek A. 5 Million Lives Campaign. Case study: an MRSA intervention at Evanston Northwestern Healthcare. Jt Comm J Qual Patient Saf 2007; 33:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/51\">",
"      Lucet JC, Chevret S, Durand-Zaleski I, et al. Prevalence and risk factors for carriage of methicillin-resistant Staphylococcus aureus at admission to the intensive care unit: results of a multicenter study. Arch Intern Med 2003; 163:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/52\">",
"      Furuno JP, McGregor JC, Harris AD, et al. Identifying groups at high risk for carriage of antibiotic-resistant bacteria. Arch Intern Med 2006; 166:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/53\">",
"      Hidron AI, Kourbatova EV, Halvosa JS, et al. Risk factors for colonization with methicillin-resistant Staphylococcus aureus (MRSA) in patients admitted to an urban hospital: emergence of community-associated MRSA nasal carriage. Clin Infect Dis 2005; 41:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/54\">",
"      Furuno JP, Harris AD, Wright MO, et al. Value of performing active surveillance cultures on intensive care unit discharge for detection of methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 2007; 28:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/55\">",
"      Harris AD, Furuno JP, Roghmann MC, et al. Targeted surveillance of methicillin-resistant Staphylococcus aureus and its potential use to guide empiric antibiotic therapy. Antimicrob Agents Chemother 2010; 54:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/56\">",
"      Harbarth S, Masuet-Aumatell C, Schrenzel J, et al. Evaluation of rapid screening and pre-emptive contact isolation for detecting and controlling methicillin-resistant Staphylococcus aureus in critical care: an interventional cohort study. Crit Care 2006; 10:R25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/57\">",
"      Lacey S, Flaxman D, Scales J, Wilson A. The usefulness of masks in preventing transient carriage of epidemic methicillin-resistant Staphylococcus aureus by healthcare workers. J Hosp Infect 2001; 48:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/58\">",
"      Mody L, Kauffman CA, Donabedian S, et al. Epidemiology of Staphylococcus aureus colonization in nursing home residents. Clin Infect Dis 2008; 46:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/59\">",
"      Miller LG, Diep BA. Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008; 46:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/60\">",
"      Loeb MB, Main C, Eady A, Walker-Dilks C. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database Syst Rev 2003; :CD003340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/61\">",
"      Harbarth S, Dharan S, Liassine N, et al. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/62\">",
"      van Rijen M, Bonten M, Wenzel R, Kluytmans J. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst Rev 2008; :CD006216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/63\">",
"      Jernigan JA, Pullen AL, Flowers L, et al. Prevalence of and risk factors for colonization with methicillin-resistant Staphylococcus aureus at the time of hospital admission. Infect Control Hosp Epidemiol 2003; 24:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/64\">",
"      van Rijen MM, Bonten M, Wenzel RP, Kluytmans JA. Intranasal mupirocin for reduction of Staphylococcus aureus infections in surgical patients with nasal carriage: a systematic review. J Antimicrob Chemother 2008; 61:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/65\">",
"      Bode LG, Kluytmans JA, Wertheim HF, et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med 2010; 362:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/66\">",
"      Kim DH, Spencer M, Davidson SM, et al. Institutional prescreening for detection and eradication of methicillin-resistant Staphylococcus aureus in patients undergoing elective orthopaedic surgery. J Bone Joint Surg Am 2010; 92:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/67\">",
"      Walsh EE, Greene L, Kirshner R. Sustained reduction in methicillin-resistant Staphylococcus aureus wound infections after cardiothoracic surgery. Arch Intern Med 2011; 171:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/68\">",
"      Doebbeling BN, Breneman DL, Neu HC, et al. Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. The Mupirocin Collaborative Study Group. Clin Infect Dis 1993; 17:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/69\">",
"      Doebbeling BN, Reagan DR, Pfaller MA, et al. Long-term efficacy of intranasal mupirocin ointment. A prospective cohort study of Staphylococcus aureus carriage. Arch Intern Med 1994; 154:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/70\">",
"      P&eacute;rez-Font&aacute;n M, Garc&iacute;a-Falc&oacute;n T, Rosales M, et al. Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long-term results. Am J Kidney Dis 1993; 22:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/71\">",
"      Bommer J, Vergetis W, Andrassy K, et al. Elimination of Staphylococcus aureus in hemodialysis patients. ASAIO J 1995; 41:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/72\">",
"      Martin JN, Perdreau-Remington F, Kartalija M, et al. A randomized clinical trial of mupirocin in the eradication of Staphylococcus aureus nasal carriage in human immunodeficiency virus disease. J Infect Dis 1999; 180:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/73\">",
"      Simor AE, Phillips E, McGeer A, et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis 2007; 44:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/74\">",
"      Buehlmann M, Frei R, Fenner L, et al. Highly effective regimen for decolonization of methicillin-resistant Staphylococcus aureus carriers. Infect Control Hosp Epidemiol 2008; 29:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/75\">",
"      Bradley SF. Eradication or decolonization of methicillin-resistant Staphylococcus aureus carriage: what are we doing and why are we doing it? Clin Infect Dis 2007; 44:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/76\">",
"      Strausbaugh LJ, Jacobson C, Sewell DL, et al. Antimicrobial therapy for methicillin-resistant Staphylococcus aureus colonization in residents and staff of a Veterans Affairs nursing home care unit. Infect Control Hosp Epidemiol 1992; 13:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/77\">",
"      Walsh TJ, Standiford HC, Reboli AC, et al. Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob Agents Chemother 1993; 37:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/78\">",
"      Sandri AM, Dalarosa MG, Ruschel de Alcantara L, et al. Reduction in incidence of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection in an intensive care unit: role of treatment with mupirocin ointment and chlorhexidine baths for nasal carriers of MRSA. Infect Control Hosp Epidemiol 2006; 27:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/79\">",
"      Watanakunakorn C, Brandt J, Durkin P, et al. The efficacy of mupirocin ointment and chlorhexidine body scrubs in the eradication of nasal carriage of Staphylococcus aureus among patients undergoing long-term hemodialysis. Am J Infect Control 1992; 20:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/80\">",
"      Boyce JM. Preventing staphylococcal infections by eradicating nasal carriage of Staphylococcus aureus: proceeding with caution. Infect Control Hosp Epidemiol 1996; 17:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/81\">",
"      Bradley SF, Ramsey MA, Morton TM, Kauffman CA. Mupirocin resistance: clinical and molecular epidemiology. Infect Control Hosp Epidemiol 1995; 16:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/82\">",
"      Jones JC, Rogers TJ, Brookmeyer P, et al. Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. Clin Infect Dis 2007; 45:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/83\">",
"      Simor AE, Stuart TL, Louie L, et al. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals. Antimicrob Agents Chemother 2007; 51:3880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/84\">",
"      Miller MA, Dascal A, Portnoy J, Mendelson J. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 1996; 17:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/85\">",
"      Diep BA, Gill SR, Chang RF, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 2006; 367:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/86\">",
"      Driscoll DG, Young CL, Ochsner UA. Transient loss of high-level mupirocin resistance in Staphylococcus aureus due to MupA polymorphism. Antimicrob Agents Chemother 2007; 51:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/87\">",
"      Mody L, Kauffman CA, McNeil SA, et al. Mupirocin-based decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37:1467.",
"     </a>",
"    </li>",
"    <li>",
"     Bradley SF. Mupirocin. In: Antimicrobial chemotherapy and vaccines, Yu VL, Weber R, Raoult D (Eds), Esun Technologies, Pittsburgh 2005. Vol II, p.293.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/89\">",
"      Ellis MW, Griffith ME, Dooley DP, et al. Targeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin-resistant Staphylococcus aureus strains in soldiers: a cluster randomized controlled trial. Antimicrob Agents Chemother 2007; 51:3591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/90\">",
"      Milstone AM, Passaretti CL, Perl TM. Chlorhexidine: expanding the armamentarium for infection control and prevention. Clin Infect Dis 2008; 46:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/91\">",
"      Wendt C, Schinke S, W&uuml;rttemberger M, et al. Value of whole-body washing with chlorhexidine for the eradication of methicillin-resistant Staphylococcus aureus: a randomized, placebo-controlled, double-blind clinical trial. Infect Control Hosp Epidemiol 2007; 28:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/92\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/ncidod/dhqp/ar_mrsa_ca_04meeting.html (Accessed on June 24, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/94\">",
"      Ammerlaan HS, Kluytmans JA, Wertheim HF, et al. Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review. Clin Infect Dis 2009; 48:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/95\">",
"      Lee AS, Macedo-Vinas M, Fran&ccedil;ois P, et al. Impact of combined low-level mupirocin and genotypic chlorhexidine resistance on persistent methicillin-resistant Staphylococcus aureus carriage after decolonization therapy: a case-control study. Clin Infect Dis 2011; 52:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/96\">",
"      Huskins WC, O'Grady NP, Samore M, et al. Design and methodology of the Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR-ICU) trial. Infect Control Hosp Epidemiol 2007; 28:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/97\">",
"      Pittet D, Hugonnet S, Harbarth S, et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. Lancet 2000; 356:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/98\">",
"      Rutala WA, Stiegel MM, Sarubbi FA, Weber DJ. Susceptibility of antibiotic-susceptible and antibiotic-resistant hospital bacteria to disinfectants. Infect Control Hosp Epidemiol 1997; 18:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/99\">",
"      Dancer SJ. Importance of the environment in meticillin-resistant Staphylococcus aureus acquisition: the case for hospital cleaning. Lancet Infect Dis 2008; 8:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/100\">",
"      Carling PC, Parry MF, Bruno-Murtha LA, Dick B. Improving environmental hygiene in 27 intensive care units to decrease multidrug-resistant bacterial transmission. Crit Care Med 2010; 38:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/101\">",
"      Rutala WA, Gergen MF, Weber DJ. Room decontamination with UV radiation. Infect Control Hosp Epidemiol 2010; 31:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/102\">",
"      Datta R, Platt R, Yokoe DS, Huang SS. Environmental cleaning intervention and risk of acquiring multidrug-resistant organisms from prior room occupants. Arch Intern Med 2011; 171:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/103\">",
"      Kunin CM, Tupasi T, Craig WA. Use of antibiotics. A brief exposition of the problem and some tentative solutions. Ann Intern Med 1973; 79:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/104\">",
"      Shlaes DM, Gerding DN, John JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/105\">",
"      Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/106\">",
"      Monnet DL. Methicillin-resistant Staphylococcus aureus and its relationship to antimicrobial use: possible implications for control. Infect Control Hosp Epidemiol 1998; 19:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/107\">",
"      Dancer SJ. The effect of antibiotics on methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2008; 61:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/108\">",
"      Dziekan G, Hahn A, Th&uuml;ne K, et al. Methicillin-resistant Staphylococcus aureus in a teaching hospital: investigation of nosocomial transmission using a matched case-control study. J Hosp Infect 2000; 46:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/109\">",
"      Hori S, Sunley R, Tami A, Grundmann H. The Nottingham Staphylococcus aureus population study: prevalence of MRSA among the elderly in a university hospital. J Hosp Infect 2002; 50:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/110\">",
"      Campillo B, Dupeyron C, Richardet JP. Epidemiology of hospital-acquired infections in cirrhotic patients: effect of carriage of methicillin-resistant Staphylococcus aureus and influence of previous antibiotic therapy and norfloxacin prophylaxis. Epidemiol Infect 2001; 127:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/111\">",
"      Fukatsu K, Saito H, Matsuda T, et al. Influences of type and duration of antimicrobial prophylaxis on an outbreak of methicillin-resistant Staphylococcus aureus and on the incidence of wound infection. Arch Surg 1997; 132:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/112\">",
"      Landman D, Chockalingam M, Quale JM. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary. Clin Infect Dis 1999; 28:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/113\">",
"      Tacconelli E, De Angelis G, Cataldo MA, et al. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother 2008; 61:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/114\">",
"      Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159.",
"     </a>",
"    </li>",
"    <li>",
"     Gorwitz RJ, Jernigan DB, Powers JH, et al. Strategies for clinical management of MRSA in the community: Summary of an experts' meeting convened by the Centers for Disease Control and Prevention. 2006. Available at: www.cdc.gov/ncidod/dhqp/pdf/ar/CAMRSA_ExpMtgStrategies.pdf (Accessed on April 14, 2008).",
"    </li>",
"    <li>",
"     file://www.cdc.gov/ncidod/dhqp/ar_mrsa_ca_public.html (Accessed on April 14, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/117\">",
"      Johansson PJ, Gustafsson EB, Ringberg H. High prevalence of MRSA in household contacts. Scand J Infect Dis 2007; 39:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/118\">",
"      Strommenger B, Kehrenberg C, Kettlitz C, et al. Molecular characterization of methicillin-resistant Staphylococcus aureus strains from pet animals and their relationship to human isolates. J Antimicrob Chemother 2006; 57:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/59/17338/abstract/119\">",
"      Boost MV, O'Donoghue MM, Siu KH. Characterisation of methicillin-resistant Staphylococcus aureus isolates from dogs and their owners. Clin Microbiol Infect 2007; 13:731.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4048 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-537ACF1ECA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_59_17338=[""].join("\n");
var outline_f16_59_17338=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SURVEILLANCE AND PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cost effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Surveillance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATIENT BATHING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DECOLONIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6351471\">",
"      - Patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Health care workers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Durability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Topical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Suggested approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      WOUND CARE AND HAND HYGIENE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ENVIRONMENTAL CLEANING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ANTIBIOTIC STEWARDSHIP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      IN THE COMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/4048\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/4048|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/9/5275\" title=\"table 1\">",
"      Risk factors for MRSA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10805?source=related_link\">",
"      Controversies in control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15575?source=related_link\">",
"      Microbiology of methicillin-resistant Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/4/22595?source=related_link\">",
"      Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31654?source=related_link\">",
"      Rapid detection of methicillin-resistant Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_59_17339="Categories retinal vasculitis";
var content_f16_59_17339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of retinal vasculitis by involved vessel",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Primary vessel involved",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyarteritis nodosa",
"       </td>",
"       <td>",
"        Muscular arteries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulomatosis with polyangiitis (Wegener's); giant cell arteritis",
"       </td>",
"       <td>",
"        Medium to small arteries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus",
"       </td>",
"       <td>",
"        Small arteries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Whipple's disease",
"       </td>",
"       <td>",
"        Capillaries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Behcet's disease; sarcoidosis; multiple sclerosis",
"       </td>",
"       <td>",
"        Veins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crohn's disease; relapsing polychondritis",
"       </td>",
"       <td>",
"        Arteries and veins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HLA-B27 associated conditions, such as ankylosing spondylitis",
"       </td>",
"       <td>",
"        Variable or no involvement",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_59_17339=[""].join("\n");
var outline_f16_59_17339=null;
var title_f16_59_17340="Rx patients with lymphatic filariasis_onchocerciasis and or loiasis";
var content_f16_59_17340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83530&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83530&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Approach to treatment of a patient with lymphatic filariasis, onchocerciasis, and/or loiasis*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Lymphatic filariasis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Onchocerciasis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Loiasis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment regimen of choice",
"       </td>",
"       <td class=\"subtitle1\">",
"        Contraindicated agent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td>",
"        Diethylcarbamazine",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td>",
"        Ivermectin",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td>",
"        No treatment if asymptomatic. Diethylcarbamazine (for patients with microfilariae load &lt;2500/mL; see text for approach to management of patients with microfilariae load &gt;2500/mL).",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td>",
"        Doxycycline plus ivermectin or albendazole",
"       </td>",
"       <td>",
"        Diethylcarbamazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td>",
"        No treatment if asymptomatic. Diethylcarbamazine (for patients with microfilariae load &lt;2500/mL; see text for approach to management of patients with microfilariae load &gt;2500/mL).",
"       </td>",
"       <td>",
"        Diethylcarbamazine (contraindicated for L. loa microfilariae load &gt;2500/mL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td>",
"        Doxycycline plus albendazole",
"       </td>",
"       <td>",
"        Ivermectin",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Dosing and duration are outlined in the text; see related topics.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter Weller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_59_17340=[""].join("\n");
var outline_f16_59_17340=null;
var title_f16_59_17341="Obesity and obs complications";
var content_f16_59_17341=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Results of multivariable logistic regression analysis showing the relation between obesity and selected maternal outcomes, singleton deliveries, Nova Scotia, 1988-2002",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Maternal",
"morbidity",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Moderate obesity",
"(N=9,355)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Adjusted OR*",
"       </td>",
"       <td class=\"subtitle2\">",
"        95% CI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Antepartum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PIH",
"       </td>",
"       <td>",
"        2.38",
"       </td>",
"       <td>",
"        2.24-2.52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Severe PIH (including (HELLP)",
"       </td>",
"       <td>",
"        1.56",
"       </td>",
"       <td>",
"        1.35-1.80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gestational diabetes",
"       </td>",
"       <td>",
"        2.80",
"       </td>",
"       <td>",
"        2.54-3.08",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Intrapartum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Very PTB (&lt;32 wk)",
"       </td>",
"       <td>",
"        0.89",
"       </td>",
"       <td>",
"        0.70-1.12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PTB (&lt;37 wk)",
"       </td>",
"       <td>",
"        0.96",
"       </td>",
"       <td>",
"        0.87-1.05",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Postterm (&gt;41 wk)",
"       </td>",
"       <td>",
"        1.18",
"       </td>",
"       <td>",
"        1.08-1.28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Labor induction",
"       </td>",
"       <td>",
"        1.94",
"       </td>",
"       <td>",
"        1.86-2.04",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cesarean delivery",
"       </td>",
"       <td>",
"        1.60",
"       </td>",
"       <td>",
"        1.53-1.67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anesthesia complications",
"       </td>",
"       <td>",
"        1.18",
"       </td>",
"       <td>",
"        1.00-1.39",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Augmentation",
"       </td>",
"       <td>",
"        1.25",
"       </td>",
"       <td>",
"        1.18-1.33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prolonged 2nd stage (&gt;3 h)",
"       </td>",
"       <td>",
"        0.96",
"       </td>",
"       <td>",
"        0.88-1.05",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Shoulder dystocia",
"       </td>",
"       <td>",
"        1.51",
"       </td>",
"       <td>",
"        1.32-1.74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3rd- or 4th-degree laceration&bull;",
"       </td>",
"       <td>",
"        0.90",
"       </td>",
"       <td>",
"        0.72-1.11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Postpartum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Postpartum hemorrhage",
"       </td>",
"       <td>",
"        1.12",
"       </td>",
"       <td>",
"        1.02-1.22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pyrexia",
"       </td>",
"       <td>",
"        1.07",
"       </td>",
"       <td>",
"        0.95-1.19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Puerperal morbidity",
"       </td>",
"       <td>",
"        1.12",
"       </td>",
"       <td>",
"        0.90-1.40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endometritis",
"       </td>",
"       <td>",
"        1.04",
"       </td>",
"       <td>",
"        0.77-1.42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urinary tract infection",
"       </td>",
"       <td>",
"        1.15",
"       </td>",
"       <td>",
"        0.95-1.39",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Wound infection",
"       </td>",
"       <td>",
"        1.67",
"       </td>",
"       <td>",
"        1.38-2.00",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Wound dehiscence",
"       </td>",
"       <td>",
"        1.85",
"       </td>",
"       <td>",
"        1.10-3.11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prolonged hospital stay (&gt;3 d)",
"       </td>",
"       <td>",
"        0.89",
"       </td>",
"       <td>",
"        0.85-0.93",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Comparison group = 79,005 non-obese women.",
"     <br>",
"      OR: odds ratio; CI: confidence interval; PIH: pregnancy-induced hypertension; HELLP: syndrome of hemolysis, elevated liver enzymes, and low platelets; VTE: venous thromboembolism; PTB: preterm birth.",
"      <br>",
"       * Adjusted for maternal age, marital status, smoking, parity, and socioeconomic status.",
"       <br>",
"        &bull; Third- or fourth-degree laceration limited to those delivered vaginally.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Robinson, et al. Maternal outcomes in pregnancies complicated by obesity. Obstet Gynecol 2005; 106:1357. Original Table #3. p. 1361.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_59_17341=[""].join("\n");
var outline_f16_59_17341=null;
var title_f16_59_17342="Lung transplant survival by diagnosis";
var content_f16_59_17342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 503px\">",
"   <div class=\"ttl\">",
"    Survival by diagnosis for lung transplants performed in adults from January 1990 to June 2008",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 483px; height: 387px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The half-life is the estimated timepoint at which 50 percent of recipients have died. Survival was calculated using the Kaplan Meier method, based on data from transplants performed between January 1990 and June 2008, as compiled in the International Society of Heart and Lung Transplantation registry.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report 2010. J Heart Lung Transplant 2010; 29:1104.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_59_17342=[""].join("\n");
var outline_f16_59_17342=null;
var title_f16_59_17343="Meat bolus impaction Endosc";
var content_f16_59_17343=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal meat bolus impaction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 210px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy of a meat bolus impaction above a preexisting malignant esophageal stricture due to advanced squamous lung cancer. Panel A: Meat bolus completely obliterates the esophageal lumen. Panel B: Endoscopic appearance of the stricture after complete removal of the impaction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George Triadafilopoulos, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_59_17343=[""].join("\n");
var outline_f16_59_17343=null;
